# EDGAR Filing Document

**Accession Number:** 0000818479
**File Stem:** 0000818479-25-000257
**Filing Date:** 2025-11
**Character Count:** 201893
**Document Hash:** 479be95898f145ee00bf14ed29ddf0fa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000818479-25-000257.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0000818479-25-000257

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 86

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DENTSPLY SIRONA Inc.
- **CENTRAL INDEX KEY:** 0000818479
- **STANDARD INDUSTRIAL CLASSIFICATION:** DENTAL EQUIPMENT & SUPPLIES [3843]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 391434669
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16211
- **FILM NUMBER:** 251456554

**BUSINESS ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607
- **BUSINESS PHONE:** 844-546-3722

**MAIL ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DENTSPLY INTERNATIONAL INC /DE/
- **DATE OF NAME CHANGE:** 19930630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENDEX CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? xray-20250930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 10-Q**

⌧**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** 

**EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** 

**EXCHANGE ACT OF 1934**

**For the transition period from to** 

Commission File Number 0-16211

**DENTSPLY SIRONA Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| <u>Delaware</u> | <u>39-1434669</u> |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
| <u>13320 Ballantyne Corporate Place, Charlotte, North Carolina</u> | <u>28277-3607</u> |
| (Address of principal executive offices) | (Zip Code) |

---

<u>(844) 848-0137</u>

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| **Common Stock, par value $.01 per share** | **XRAY** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ⌧ | Accelerated filer ☐ |
| Non-accelerated filer ☐ | Smaller reporting company ☐ |
| | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ⌧

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: At October 17, 2025, DENTSPLY SIRONA Inc. had 199,551,969 shares of common stock outstanding.

------

**DENTSPLY SIRONA Inc.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **<u>[PART I](#i587cf739c7ae443c823919a0e592a00a_10)</u>** | **<u>[FINANCIAL INFORMATION](#i587cf739c7ae443c823919a0e592a00a_10)</u>** | **<u>Page</u>** |
| <u>[Item 1](#i587cf739c7ae443c823919a0e592a00a_13)</u> | <u>[Financial Statements (unaudited)](#i587cf739c7ae443c823919a0e592a00a_13)</u> | <u>[4](#i587cf739c7ae443c823919a0e592a00a_13)</u> |
|  | <u>[Consolidated Statements of Operations](#i587cf739c7ae443c823919a0e592a00a_16)</u> | <u>[4](#i587cf739c7ae443c823919a0e592a00a_16)</u> |
|  | <u>[Consolidated Statements of Comprehensive Income (Loss)](#i587cf739c7ae443c823919a0e592a00a_19)</u>  | <u>[5](#i587cf739c7ae443c823919a0e592a00a_19)</u> |
|  | <u>[Consolidated Balance Sheets](#i587cf739c7ae443c823919a0e592a00a_22)</u> | <u>[6](#i587cf739c7ae443c823919a0e592a00a_22)</u> |
|  | <u>[Consolidated Statements of Changes in Equity](#i587cf739c7ae443c823919a0e592a00a_25)</u> | <u>[7](#i587cf739c7ae443c823919a0e592a00a_25)</u> |
|  | <u>[Consolidated Statements of Cash Flows](#i587cf739c7ae443c823919a0e592a00a_28)</u> | <u>[9](#i587cf739c7ae443c823919a0e592a00a_28)</u> |
|  | <u>[Notes to Unaudited Interim Consolidated Financial Statements](#i587cf739c7ae443c823919a0e592a00a_31)</u> | <u>[9](#i587cf739c7ae443c823919a0e592a00a_31)</u> |
| <u>[Item 2](#i587cf739c7ae443c823919a0e592a00a_103)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i587cf739c7ae443c823919a0e592a00a_103)</u> | <u>[37](#i587cf739c7ae443c823919a0e592a00a_103)</u> |
| <u>[Item 3](#i587cf739c7ae443c823919a0e592a00a_115)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i587cf739c7ae443c823919a0e592a00a_115)</u> | <u>[51](#i587cf739c7ae443c823919a0e592a00a_115)</u> |
| <u>[Item 4](#i587cf739c7ae443c823919a0e592a00a_118)</u> | <u>[Controls and Procedures](#i587cf739c7ae443c823919a0e592a00a_118)</u> | <u>[51](#i587cf739c7ae443c823919a0e592a00a_118)</u> |
| **<u>[PART II](#i587cf739c7ae443c823919a0e592a00a_121)</u>** | **<u>[OTHER INFORMATION](#i587cf739c7ae443c823919a0e592a00a_121)</u>** |  |
| <u>[Item 1](#i587cf739c7ae443c823919a0e592a00a_124)</u> | <u>[Legal Proceedings](#i587cf739c7ae443c823919a0e592a00a_124)</u> | <u>[52](#i587cf739c7ae443c823919a0e592a00a_124)</u> |
| <u>[Item 1A](#i587cf739c7ae443c823919a0e592a00a_127)</u> | <u>[Risk Factors](#i587cf739c7ae443c823919a0e592a00a_127)</u> | <u>[52](#i587cf739c7ae443c823919a0e592a00a_127)</u> |
| <u>[Item 2](#i587cf739c7ae443c823919a0e592a00a_130)</u> | <u>[Unregistered Sales of Securities and Use of Proceeds](#i587cf739c7ae443c823919a0e592a00a_130)</u> | <u>[54](#i587cf739c7ae443c823919a0e592a00a_130)</u> |
| <u>[Item 5](#i587cf739c7ae443c823919a0e592a00a_133)</u> | <u>[Other Information](#i587cf739c7ae443c823919a0e592a00a_133)</u> | <u>[54](#i587cf739c7ae443c823919a0e592a00a_133)</u> |
| <u>[Item 6](#i587cf739c7ae443c823919a0e592a00a_136)</u> | <u>[Exhibits](#i587cf739c7ae443c823919a0e592a00a_136)</u> | <u>[55](#i587cf739c7ae443c823919a0e592a00a_136)</u> |
| <u>[Signatures](#i587cf739c7ae443c823919a0e592a00a_139)</u> |  | <u>[56](#i587cf739c7ae443c823919a0e592a00a_139)</u> |

---

------

**<u>General</u>**

Unless otherwise stated herein or the context otherwise indicates, references throughout this Form 10-Q to "Dentsply Sirona," or the "Company," "we," "us" or "our" refer to DENTSPLY SIRONA Inc., together with its subsidiaries on a consolidated basis.

**<u>Forward-Looking Statements and Associated Risks</u>**

All statements in this Form 10-Q that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

**<u>Disclosure Regarding Trademarks</u>**

This report includes trademarks, trade names and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and trade names sometimes appear without any "™" or "®" symbol. Failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and trade names.

------

**PART I – FINANCIAL INFORMATION**

**Item 1 – Financial Statements**

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

(in millions, except per share amounts)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| | 2025 | 2024 | 2025 | 2024 |
| Net sales | $904 | $951 | $2719 | $2888 |
| Cost of products sold | 463 | 456 | 1322 | 1376 |
| Gross profit | 441 | 495 | 1397 | 1512 |
| Selling, general, and administrative expenses | 355 | 390 | 1055 | 1204 |
| Research and development expenses | 37 | 40 | 110 | 123 |
| Goodwill and intangible asset impairments | 262 | 504 | 497 | 510 |
| Restructuring and other costs | 5 | 23 | 18 | 45 |
| Operating loss | (218) | (462) | (283) | (370) |
| Other income and expenses: |  |  |  |  |
| &nbsp;&nbsp;Interest expense, net | 23 | 18 | 66 | 53 |
| &nbsp;&nbsp;Other income | (11) | (2) | (10) | (10) |
| Loss before income taxes | (230) | (478) | (339) | (413) |
| Provision for income taxes | 198 | 17 | 114 | 69 |
| Net loss | (428) | (495) | (453) | (482) |
| Less: Net loss attributable to noncontrolling interest | (1) | (1) | (1) | (2) |
| Net loss attributable to Dentsply Sirona | $(427) | $(494) | $(452) | $(480) |
| Loss per common share attributable to Dentsply Sirona: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(2.14) | $(2.46) | $(2.27) | $(2.35) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(2.14) | $(2.46) | $(2.27) | $(2.35) |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 199.5 | 201.0 | 199.3 | 204.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 199.5 | 201.0 | 199.3 | 204.7 |

---

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

(in millions)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| | 2025 | 2024 | 2025 | 2024 |
| Net loss | $(428) | $(495) | $(453) | $(482) |
| Other comprehensive (loss) income, net of tax: |  |  |  |  |
| &nbsp;&nbsp; Foreign currency translation (loss) gain | (8) | 75 | 185 | 3 |
| &nbsp;&nbsp; Net loss on derivative financial instruments | (23) | (36) | (127) | (5) |
| Total other comprehensive (loss) income, net of tax | (31) | 39 | 58 | (2) |
| Total comprehensive loss | (459) | (456) | (395) | (484) |
| Less: Comprehensive loss attributable to noncontrolling interests | (1) | (1) | (1) | (2) |
| Total comprehensive loss attributable to Dentsply Sirona | $(458) | $(455) | $(394) | $(482) |

---

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

(in millions, except share and per share amounts)

(unaudited)

---

| | | |
|:---|:---|:---|
| | September 30, 2025 | December 31, 2024 |
| **Assets** |  |  |
| &nbsp;&nbsp;Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $363 | $272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | 654 | 556 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 686 | 564 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 369 | 354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 2072 | 1746 |
| &nbsp;&nbsp;Property, plant, and equipment, net | 841 | 766 |
| &nbsp;&nbsp;Operating lease right-of-use assets, net | 131 | 136 |
| &nbsp;&nbsp;Identifiable intangible assets, net | 1065 | 1207 |
| &nbsp;&nbsp;Goodwill | 1270 | 1597 |
| &nbsp;&nbsp;Other noncurrent assets | 274 | 301 |
| Total Assets | $5653 | $5753 |
| **Liabilities and Equity** |  |  |
| &nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $268 | $241 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 712 | 754 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 47 | 45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable and current portion of long-term debt | 378 | 549 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 1405 | 1589 |
| &nbsp;&nbsp;Long-term debt | 2017 | 1586 |
| &nbsp;&nbsp;Operating lease liabilities | 85 | 91 |
| &nbsp;&nbsp;Deferred income taxes | 95 | 129 |
| &nbsp;&nbsp;Other noncurrent liabilities | 573 | 415 |
| Total Liabilities | 4175 | 3810 |
| &nbsp;&nbsp;Commitments and contingencies (Note 14) |  |  |
| &nbsp;&nbsp;Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.01 par value; | 3 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;400.0 million shares authorized, and 264.5 million shares issued at September 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;199.5 million and 198.8 million shares outstanding at September 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital in excess of par value | 6638 | 6640 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1385) | (835) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (672) | (730) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 65.0 million and 65.7 million shares at September 30, 2025 and December 31, 2024, respectively | (3106) | (3136) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Dentsply Sirona Equity | 1478 | 1942 |
| &nbsp;&nbsp;Noncontrolling interests |  | 1 |
| &nbsp;&nbsp;Total Equity | 1478 | 1943 |
| Total Liabilities and Equity | $5653 | $5753 |

---

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

(in millions, except per share amounts)

(unaudited)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common<br>Stock | Capital in<br>Excess of<br>Par Value | Accumulated<br>Deficit | Accumulated<br>Other<br>Comprehensive<br>Loss | Treasury<br>Stock | Total Dentsply Sirona<br>Equity | Noncontrolling<br>Interests | Total<br>Equity |
| **Balance at December 31, 2024** | $3 | $6640 | $(835) | $(730) | $(3136) | $1942 | $1 | $1943 |
| Net income (loss) |  |  | 20 |  |  | 20 | (1) | 19 |
| Other comprehensive income |  |  |  | 71 |  | 71 |  | 71 |
| Stock-based compensation expense |  | 10 |  |  |  | 10 |  | 10 |
| Funding of employee stock purchase plan |  | (3) |  |  | 5 | 2 |  | 2 |
| Restricted stock unit distributions |  | (17) |  |  | 14 | (3) |  | (3) |
| Restricted stock unit dividends |  | 1 | (1) |  |  |  |  |  |
| Cash dividends declared ($0.16 per share) |  |  | (32) |  |  | (32) |  | (32) |
| **Balance at March 31, 2025** | $3 | $6631 | $(848) | $(659) | $(3117) | $2010 | $— | $2010 |
| Net (loss) income |  |  | (45) |  |  | (45) | 1 | (44) |
| Other comprehensive income |  |  |  | 18 |  | 18 |  | 18 |
| Stock-based compensation expense |  | 9 |  |  |  | 9 |  | 9 |
| Restricted stock unit distributions |  | (2) |  |  | 2 |  |  |  |
| Cash dividends declared ($0.16 per share) |  |  | (32) |  |  | (32) |  | (32) |
| **Balance at June 30, 2025** | $3 | $6638 | $(925) | $(641) | $(3115) | $1960 | $1 | $1961 |
| Net income (loss) |  |  | (427) |  |  | (427) | (1) | (428) |
| Other comprehensive income |  |  |  | (31) |  | (31) |  | (31) |
| Stock-based compensation expense |  | 6 |  |  |  | 6 |  | 6 |
| Funding of employee stock purchase plan |  | (4) |  |  | 6 | 2 |  | 2 |
| Restricted stock unit distributions |  | (3) |  |  | 3 |  |  |  |
| Restricted stock unit dividends |  | 1 | (1) |  |  |  |  |  |
| Cash dividends declared ($0.16 per share) |  |  | (32) |  |  | (32) |  | (32) |
| **Balance at September 30, 2025** | $3 | $6638 | $(1385) | $(672) | $(3106) | $1478 | $— | $1478 |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common<br>Stock | Capital in<br>Excess of<br>Par Value | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive<br>Loss | Treasury<br>Stock | Total Dentsply Sirona<br>Equity | Noncontrolling<br>Interests | Total<br>Equity |
| **Balance at December 31, 2023** | $3 | $6643 | $205 | $(636) | $(2922) | $3293 | $1 | $3294 |
| Net income (loss) |  |  | 18 |  |  | 18 | (1) | 17 |
| Other comprehensive loss |  |  |  | (30) |  | (30) |  | (30) |
| Stock-based compensation expense |  | 11 |  |  |  | 11 |  | 11 |
| Funding of employee stock purchase plan |  |  |  |  | 3 | 3 |  | 3 |
| Restricted stock unit distributions |  | (15) |  |  | 11 | (4) |  | (4) |
| Cash dividends declared ($0.16 per share) |  |  | (33) |  |  | (33) |  | (33) |
| **Balance at March 31, 2024** | $3 | $6639 | $190 | $(666) | $(2908) | $3258 | $— | $3258 |
| Net loss |  |  | (4) |  |  | (4) |  | (4) |
| Other comprehensive loss |  |  |  | (11) |  | (11) |  | (11) |
| Stock-based compensation expense |  | 12 |  |  |  | 12 |  | 12 |
| Treasury shares purchased |  |  |  |  | (152) | (152) |  | (152) |
| Restricted stock unit distributions |  | (20) |  |  | 15 | (5) |  | (5) |
| Cash dividends declared ($0.16 per share) |  |  | (34) |  |  | (34) |  | (34) |
| **Balance at June 30, 2024** | $3 | $6631 | $152 | $(677) | $(3045) | $3064 | $— | $3064 |
| Net loss |  |  | (494) |  |  | (494) | (1) | (495) |
| Other comprehensive income |  |  |  | 39 |  | 39 |  | 39 |
| Stock-based compensation expense |  | 12 |  |  |  | 12 |  | 12 |
| Funding of employee stock purchase plan |  | (2) |  |  | 5 | 3 |  | 3 |
| Treasury shares purchased |  |  |  |  | (101) | (101) |  | (101) |
| Restricted stock unit distributions |  | (3) |  |  | 2 | (1) |  | (1) |
| Restricted stock unit dividends |  | 1 | (1) |  |  |  |  |  |
| Cash dividends ($0.16 per share) |  |  | (31) |  |  | (31) |  | (31) |
| **Balance at September 30, 2024** | $3 | $6639 | $(374) | $(638) | $(3139) | $2491 | $(1) | $2490 |

---

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in millions)

(unaudited)

---

| | | |
|:---|:---|:---|
| | Nine Months Ended September 30, | Nine Months Ended September 30, |
| | 2025 | 2024 |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(453) | $(482) |
| Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation | 104 | 99 |
| &nbsp;&nbsp;Amortization of intangible assets | 155 | 162 |
| &nbsp;&nbsp;Goodwill asset impairment | 409 | 504 |
| &nbsp;&nbsp;Indefinite-lived intangible asset impairment | 88 | 6 |
| &nbsp;&nbsp;Deferred income taxes | 44 | (20) |
| &nbsp;&nbsp;Stock-based compensation expense | 25 | 35 |
| &nbsp;&nbsp;Other non-cash expense | 13 | 36 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | (56) | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | (61) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (10) | 61 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent assets |  | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (9) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (66) | (17) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (45) | (15) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent liabilities | (4) | (4) |
| **Net cash provided by operating activities** | 134 | 374 |
| **Cash flows from investing activities:** |  |  |
| Capital expenditures | (90) | (129) |
| Cash received on derivative contracts | 10 |  |
| Cash paid on derivative contracts | (9) | (12) |
| Other investing activities | 2 | 1 |
| **Net cash used in investing activities** | (87) | (140) |
| **Cash flows from financing activities:** |  |  |
| Cash paid for treasury stock |  | (250) |
| Proceeds from 364-day bridge loan | 435 |  |
| Repayment of 364-day bridge loan | (435) |  |
| (Repayments) proceeds on other short-term borrowings, net | (416) | 99 |
| Cash dividends paid | (96) | (95) |
| Proceeds from long-term borrowings | 551 |  |
| Repayments on long-term borrowings | (3) | (8) |
| Cash paid for deferred financing costs | (13) |  |
| Other financing activities, net | (4) | (10) |
| **Net cash provided by (used in) financing activities** | 19 | (264) |
| Effect of exchange rate changes on cash and cash equivalents | 25 | (8) |
| Net increase (decrease) in cash and cash equivalents | 91 | (38) |
| Cash and cash equivalents at beginning of period | 272 | 334 |
| Cash and cash equivalents at end of period | $363 | $296 |
| Non-cash investing activities: |  |  |
| &nbsp;&nbsp;Property, plant and equipment in accounts payable at end of period | $25 | $28 |
| &nbsp;&nbsp;Exchange of inventory for naming and other rights | $14 | $— |

---

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

------

**DENTSPLY SIRONA Inc. and Subsidiaries**

**<u>NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</u>**

**NOTE 1 – BUSINESS AND BASIS OF PRESENTATION**

**Basis of Presentation**

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and the rules of the U.S. Securities and Exchange Commission ("SEC"). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Certain prior period amounts have been reclassified to conform to current year presentation. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries ("Dentsply Sirona" or the "Company") on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company's most recent Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 27, 2025 (the "2024 Form 10-K").

**Use of Estimates**

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net sales and expense during the reporting period. Actual results could differ materially from those estimates.

**Recently Adopted Accounting Pronouncements**

In December 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which requires public entities to disclose additional income tax information, primarily related to the income tax rate reconciliation and income taxes paid on an annual basis. The amendments are intended to enhance the transparency and decision-usefulness of income tax disclosures. The Company has adopted this accounting standard as of January 1, 2025, which impacts annual disclosures only. This update did not have an impact to results of operations, financial position, or cash flows.

**Accounting Pronouncements Not Yet Adopted**

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses," which requires disaggregated disclosure of income statement expenses for public business entities ("PBEs"). In January 2025, the FASB issued ASU No. 2025-01 "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)," which clarified the effective date for ASU No. 2024-03. These amendments are intended to provide more information about types of expenses in commonly presented expense captions. The amendments in this update are effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20) Induced Conversions of Convertible Debt Instruments," which amends ASC 470-202 to clarify the requirements related to accounting for the settlement of a debt instrument as an induced conversion. The amendments in this update are effective for annual periods beginning after December 15, 2025, and interim periods within those annual reporting periods, and early adoption is permitted if the entity has also adopted ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40)" for that period. The Company does not anticipate that this update will materially impact the Company's consolidated financial statements and related disclosures.

------

In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)," which amends certain aspects of ASC 350-40 related to the accounting and disclosure of internally developed software costs. This amendment is intended to provide further guidance on how to evaluate whether the probable-to-complete recognition threshold has been met to capitalize costs for internal-use software. The amendments in this update are effective for annual periods beginning after December 15, 2027 and interim periods within those annual reporting periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued or made available for issuance. Entities may apply the guidance prospectively, retrospectively, or via a modified prospective transition method. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU No. 2025-07, "Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606)," which refines the scope of the guidance in ASC 815 and clarifies the guidance on share-based payments from a customer in ASC 606. This amendment is intended to address concerns on the application of derivative accounting to contracts that have features based on the operations or activities of one of the parties to the contract and to bring consistency in the accounting for share-based payments in revenue contracts. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim periods within those annual reporting periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued or made available for issuance. Entities may apply the guidance prospectively or on a modified retrospective basis. The Company is currently evaluating the impact on its consolidated financial statements and related disclosures.

**Seasonality**

The Company's business is subject to quarterly fluctuations in demand due to seasonality, which can impact the timing of the Company's consolidated net sales, net income, and cash flows. Demand can fluctuate based on the timing of dental tradeshows and variability in dental patient traffic, which can be exacerbated by seasonal or severe weather patterns. Some dental practices in certain countries may also delay purchasing equipment and restocking consumable products until year-end due to tax or other financial planning reasons. In addition, the timing of holidays and vacations, particularly throughout Europe, may shift demand across quarters. Sales for the industry and the Company are generally stronger in the second and fourth quarters and weaker in the first and third quarters, due to the effects of the items noted above. Because of the seasonal nature of the Company's business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year.

**NOTE 2 - REVENUE RECOGNITION**

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

------

Net sales disaggregated by product category were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| &nbsp;&nbsp;Equipment & Instruments | $148 | $138 | $418 | $402 |
| &nbsp;&nbsp;CAD/CAM | 111 | 131 | 319 | 367 |
| **Connected Technology Solutions** | 259 | 269 | $737 | $769 |
| **Essential Dental Solutions** | 357 | 369 | $1097 | $1108 |
| &nbsp;&nbsp;Orthodontics | 53 | 83 | $175 | $276 |
| &nbsp;&nbsp;Implants & Prosthetics | 152 | 158 | 473 | 512 |
| **Orthodontic and Implant Solutions** | 205 | 241 | $648 | $788 |
| **Wellspect Healthcare** | 83 | 72 | $237 | $223 |
| **Total net sales** | $904 | $951 | $2719 | $2888 |

---

Net sales disaggregated by geographic region were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| &nbsp;&nbsp;United States | $291 | $374 | $886 | $1089 |
| &nbsp;&nbsp;Europe | 382 | 347 | 1148 | 1110 |
| &nbsp;&nbsp;Rest of World | 231 | 230 | 685 | 689 |
| **Total net sales** | $904 | $951 | $2719 | $2888 |

---

**Contract Assets and Liabilities**

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to deferred revenue associated with loyalty points earned but not yet redeemed by customers under the Company's loyalty point program and advanced billings for customer orthodontic aligner treatments where the performance obligation has not yet been satisfied. The Company recorded deferred revenue of $88 million and $34 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at September 30, 2025. The Company recorded deferred revenue of $95 million and $49 million in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2024. During the three and nine months ended September 30, 2025, the Company recognized approximately $30 million and $88 million of net sales, respectively, which were previously deferred as of December 31, 2024. During the three and nine months ended September 30, 2024, the Company recognized approximately $14 million and $77 million of net sales, respectively, which were previously deferred as of December 31, 2023. The Company expects to recognize most of the remaining deferred revenue in net sales within the next twelve months.

**Allowance for Doubtful Accounts**

Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $12 million at September 30, 2025 and $14 million at December 31, 2024. For the three and nine months ended September 30, 2025 and 2024, changes to the provision for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were not significant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.

**NOTE 3 – STOCK-BASED COMPENSATION**

------

The amounts of stock-based compensation expense recorded in the Company's Consolidated Statements of Operations were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| &nbsp;&nbsp;Cost of products sold | $1 | $— | $2 | $2 |
| &nbsp;&nbsp;Selling, general, and administrative expense | 5 | 11 | 22 | 31 |
| &nbsp;&nbsp;Research and development expense |  | 1 | 1 | 2 |
| Total stock-based compensation expense | $6 | $12 | $25 | $35 |

---

------

**NOTE 4 – COMPREHENSIVE LOSS**

Changes in Accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (in millions) | Foreign Currency Translation Gain (Loss) | Gain (Loss) on Cash Flow Hedges | Gain (Loss) on Net Investment and Fair Value Hedges | Pension <br>Liability Gain (Loss) | Total |
| Balance, net of tax, at December 31, 2024 | $(619) | $(10) | $(70) | $(31) | $(730) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications and tax impact | 75 |  | (21) |  | 54 |
| &nbsp;&nbsp;Tax benefit | 12 |  | 5 |  | 17 |
| &nbsp;&nbsp;Other comprehensive income (loss), net of tax, before reclassifications | 87 |  | (16) |  | 71 |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net increase (decrease) in other comprehensive loss | 87 |  | (16) |  | 71 |
| Balance, net of tax, at March 31, 2025 | $(532) | $(10) | $(86) | $(31) | $(659) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications and tax impact | 75 |  | (115) |  | (40) |
| &nbsp;&nbsp;Tax benefit | 31 |  | 27 |  | 58 |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications and tax impact | 106 |  | (88) |  | 18 |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net increase (decrease) in other comprehensive loss | 106 |  | (88) |  | 18 |
| Balance, net of tax, at June 30, 2025 | $(426) | $(10) | $(174) | $(31) | $(641) |
| Other comprehensive loss before reclassifications and tax impact | (6) |  | (29) |  | (35) |
| Tax (expense) benefit | (2) |  | 6 |  | 4 |
| Other comprehensive loss, net of tax, before reclassifications | (8) |  | (23) |  | (31) |
| Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net decrease in other comprehensive income | (8) |  | (23) |  | (31) |
| Foreign currency translation related to acquisition of noncontrolling interests |  |  |  |  |  |
| Balance, net of tax, at September 30, 2025 | $(434) | $(10) | $(197) | $(31) | $(672) |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (in millions) | Foreign Currency Translation Gain (Loss) | Gain (Loss) on Cash Flow Hedges | Gain (Loss) on Net Investment and Fair Value Hedges | Pension <br>Liability Gain (Loss) | Total |
| Balance, net of tax, at December 31, 2023 | $(473) | $(13) | $(107) | $(43) | $(636) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassifications and tax impact | (34) |  | 42 |  | 8 |
| &nbsp;&nbsp;Tax expense | (28) |  | (10) |  | (38) |
| &nbsp;&nbsp;Other comprehensive (loss) income, net of tax, before reclassifications | (62) |  | 32 |  | (30) |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net (decrease) increase in other comprehensive loss | (62) |  | 32 |  | (30) |
| Balance, net of tax, at March 31, 2024 | $(535) | $(13) | $(75) | $(43) | $(666) |
| &nbsp;&nbsp;Other comprehensive loss before reclassifications and tax impact | (14) |  | (2) |  | (16) |
| &nbsp;&nbsp;Tax benefit | 4 |  | 1 |  | 5 |
| &nbsp;&nbsp;Other comprehensive loss, net of tax, before reclassifications | (10) |  | (1) |  | (11) |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net decrease in other comprehensive loss | (10) |  | (1) |  | (11) |
| Balance, net of tax, at June 30, 2024 | $(545) | $(13) | $(76) | $(43) | $(677) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications and tax impact | 58 |  | (46) |  | 12 |
| &nbsp;&nbsp;Tax benefit | 17 |  | 10 |  | 27 |
| &nbsp;&nbsp;Other comprehensive income (loss), net of tax, before reclassifications | 75 |  | (36) |  | 39 |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss), net of tax |  |  |  |  |  |
| &nbsp;&nbsp;Net decrease in other comprehensive income | 75 |  | (36) |  | 39 |
| Balance, net of tax, at September 30, 2024 | $(470) | $(13) | $(112) | $(43) | $(638) |

---

At September 30, 2025 and December 31, 2024, the cumulative tax adjustments were $197 million and $118 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of $290 million and $552 million at September 30, 2025 and December 31, 2024, respectively, and cumulative losses on loans designated as hedges of net investments of $144 million and $67 million at September 30, 2025 and December 31, 2024, respectively.

Reclassifications out of AOCI to the Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 were not significant.

------

**NOTE 5 – LOSS PER COMMON SHARE** 

The computations of basic and diluted loss per common share were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Basic loss per common share** | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except per share amounts) | 2025 | 2024 | 2025 | 2024 |
| Net loss attributable to Dentsply Sirona | $(427) | $(494) | $(452) | $(480) |
| Weighted average common shares outstanding | 199.5 | 201.0 | 199.3 | 204.7 |
| Basic loss per common share | $(2.14) | $(2.46) | $(2.27) | $(2.35) |
| **Diluted loss per common share** | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except per share amounts) | 2025 | 2024 | 2025 | 2024 |
| Net loss attributable to Dentsply Sirona | $(427) | $(494) | $(452) | $(480) |
| Weighted average common shares outstanding | 199.5 | 201.0 | 199.3 | 204.7 |
| Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards |  |  |  |  |
| Total weighted average diluted shares outstanding | 199.5 | 201.0 | 199.3 | 204.7 |
| Diluted loss per common share | $(2.14) | $(2.46) | $(2.27) | $(2.35) |
| Weighted average shares excluded from diluted common shares outstanding due to reported net loss for the period | 0.8 | 0.5 | 0.7 | 0.6 |
| Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature | 5.1 | 3.9 | 4.6 | 4.2 |

---

**NOTE 6 – SEGMENT INFORMATION**

The Company has four operating segments, organized primarily by product, which are also the Company's reportable segments. These are (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare. These operating segments are identified in accordance with how the Company's chief operating decision maker ("CODM") regularly reviews financial results and uses this information to evaluate the Company's performance and allocate resources. The Company's CODM is the Chief Executive Officer.

The Company's reportable segment information was as follows:

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, |
| (in millions) | 2025 | 2025 | 2025 | 2025 | 2025 |
|  | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total |
| Net sales | $259 | $357 | $205 | $83 | $904 |
| &nbsp;&nbsp;Adjusted cost of products sold <sup>(a)</sup> | 157 | 140 | 95 | 33 |  |
| &nbsp;&nbsp;Adjusted selling expenses <sup>(b)</sup> | 55 | 77 | 56 | 13 |  |
| &nbsp;&nbsp;Adjusted G&A expenses <sup>(b)</sup> | 20 | 18 | 20 | 7 |  |
| &nbsp;&nbsp;Adjusted R&D expenses <sup>(c)</sup> | 17 | 6 | 12 | 2 |  |
| &nbsp;&nbsp;Segment adjusted operating income | $10 | $116 | $22 | $28 | $176 |
| &nbsp;&nbsp;**Reconciling items (income) expense:** |  |  |  |  |  |
| &nbsp;&nbsp;Unallocated corporate costs <sup>(d)</sup> |  |  |  |  | $69 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  | 23 |
| &nbsp;&nbsp;Other income |  |  |  |  | (11) |
| &nbsp;&nbsp;Goodwill and intangible asset impairments |  |  |  |  | 262 |
| &nbsp;&nbsp;Restructuring and other costs |  |  |  |  | 5 |
| &nbsp;&nbsp;Amortization of intangibles |  |  |  |  | 57 |
| &nbsp;&nbsp;Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations |  |  |  |  | 1 |
| &nbsp;&nbsp;Loss before income taxes |  |  |  |  | $(230) |

---

---

| |
|:---|
| (a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs. |
| (b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs. |
| (c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs. |
| (d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, |
| (in millions) | 2024 | 2024 | 2024 | 2024 | 2024 |
|  | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total |
| Net sales | $269 | $369 | $241 | $72 | $951 |
| &nbsp;&nbsp;Adjusted cost of products sold <sup>(a)</sup> | 156 | 138 | 100 | 25 |  |
| &nbsp;&nbsp;Adjusted selling expenses <sup>(b)</sup> | 60 | 76 | 75 | 12 |  |
| &nbsp;&nbsp;Adjusted G&A expenses <sup>(b)</sup> | 19 | 17 | 29 | 7 |  |
| &nbsp;&nbsp;Adjusted R&D expenses <sup>(c)</sup> | 18 | 6 | 13 | 2 |  |
| &nbsp;&nbsp;Segment adjusted operating income | $16 | $132 | $24 | $26 | $198 |
| &nbsp;&nbsp;**Reconciling items (income) expense:** |  |  |  |  |  |
| &nbsp;&nbsp;Unallocated corporate costs <sup>(d)</sup> |  |  |  |  | $79 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  | 18 |
| &nbsp;&nbsp;Other income |  |  |  |  | (2) |
| &nbsp;&nbsp;Goodwill and intangible asset impairments |  |  |  |  | 504 |
| &nbsp;&nbsp;Restructuring and other costs |  |  |  |  | 23 |
| &nbsp;&nbsp;Amortization of intangibles |  |  |  |  | 54 |
| &nbsp;&nbsp;Loss before income taxes |  |  |  |  | $(478) |

---

---

| |
|:---|
| (a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs. |
| (b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs. |
| (c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs. |
| (d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2025 | 2025 | 2025 | 2025 |
|  | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total |
| Net sales | $737 | $1097 | $648 | $237 | $2719 |
| &nbsp;&nbsp;Adjusted cost of products sold <sup>(a)</sup> | 432 | 402 | 286 | 93 |  |
| &nbsp;&nbsp;Adjusted selling expenses <sup>(b)</sup> | 167 | 220 | 164 | 39 |  |
| &nbsp;&nbsp;Adjusted G&A expenses <sup>(b)</sup> | 58 | 55 | 59 | 20 |  |
| &nbsp;&nbsp;Adjusted R&D expenses <sup>(c)</sup> | 51 | 17 | 35 | 7 |  |
| &nbsp;&nbsp;Segment adjusted operating income | $29 | $403 | $104 | $78 | $614 |
| &nbsp;&nbsp;**Reconciling items (income) expense:** |  |  |  |  |  |
| &nbsp;&nbsp;Unallocated corporate costs <sup>(d)</sup> |  |  |  |  | $224 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  | 66 |
| &nbsp;&nbsp;Other income |  |  |  |  | (10) |
| &nbsp;&nbsp;Goodwill and intangible asset impairments |  |  |  |  | 497 |
| &nbsp;&nbsp;Restructuring and other costs |  |  |  |  | 18 |
| &nbsp;&nbsp;Amortization of intangibles |  |  |  |  | 156 |
| &nbsp;&nbsp;Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations |  |  |  |  | 2 |
| Loss before income taxes |  |  |  |  | $(339) |

---

---

| |
|:---|
| (a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs. |
| (b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs. |
| (c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs. |
| (d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2024 | 2024 | 2024 | 2024 | 2024 |
|  | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total |
| Net sales | $769 | $1108 | $788 | $223 | $2888 |
| &nbsp;&nbsp;Adjusted cost of products sold <sup>(a)</sup> | 452 | 424 | 307 | 83 |  |
| &nbsp;&nbsp;Adjusted selling expenses <sup>(b)</sup> | 183 | 239 | 238 | 39 |  |
| &nbsp;&nbsp;Adjusted G&A expenses <sup>(b)</sup> | 57 | 56 | 96 | 21 |  |
| &nbsp;&nbsp;Adjusted R&D expenses <sup>(c)</sup> | 56 | 17 | 39 | 7 |  |
| &nbsp;&nbsp;Segment adjusted operating income | $21 | $372 | $108 | $73 | $574 |
| &nbsp;&nbsp;**Reconciling items (income) expense:** |  |  |  |  |  |
| &nbsp;&nbsp;Unallocated corporate costs <sup>(d)</sup> |  |  |  |  | $227 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  | 53 |
| &nbsp;&nbsp;Other income |  |  |  |  | (10) |
| &nbsp;&nbsp;Goodwill and intangible asset impairments |  |  |  |  | 510 |
| &nbsp;&nbsp;Restructuring and other costs |  |  |  |  | 45 |
| &nbsp;&nbsp;Amortization of intangibles |  |  |  |  | 162 |
| Loss before income taxes |  |  |  |  | $(413) |

---

---

| |
|:---|
| (a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs. |
| (b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs. |
| (c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs. |
| (d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment. |

---

<u>Depreciation and Amortization</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| Connected Technology Solutions | 48 | 44 | 137 | 130 |
| Essential Dental Solutions | 9 | 9 | 26 | 26 |
| Orthodontic and Implant Solutions | 24 | 25 | 66 | 75 |
| Wellspect Healthcare | 5 | 5 | 13 | 14 |
| All other <sup>(a)</sup> | 6 | 6 | 17 | 16 |
| &nbsp;&nbsp;Total | 92 | 89 | 259 | 261 |

---

(a) Includes unallocated corporate costs for depreciation and amortization.

------

**NOTE 7 – INVENTORIES**

Inventories, net were as follows:

---

| | | |
|:---|:---|:---|
| (in millions) | September 30, 2025 | December 31, 2024 |
| Raw materials and supplies | $198 | $172 |
| Work-in-process | 86 | 72 |
| Finished goods | 402 | 320 |
| &nbsp;&nbsp;Inventories, net | $686 | $564 |

---

The Company's inventory reserve was $102 million and $98 million at September 30, 2025 and December 31, 2024, respectively.

**NOTE 8 – RESTRUCTURING AND OTHER COSTS** 

Restructuring and other costs were recorded in the Consolidated Statements of Operations as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| Cost of products sold | $— | $— | $— | $1 |
| Selling, general, and administrative expenses |  | 2 | 1 | 6 |
| Restructuring and other costs | 5 | 23 | 18 | 45 |
| &nbsp;&nbsp;Total restructuring and other costs | $5 | $25 | $19 | $52 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Restructuring and other costs of $5 million and $18 million recorded in the three and nine months ended September 30, 2025 consisted primarily of employee severance benefits and other restructuring costs for various restructuring actions, including the continuation of the global supply chain transformation initiatives from prior years, and for the plan approved by the Board of Directors of the Company on July 29, 2024 (the "2024 Plan").

With the 2024 Plan, the Company seeks to improve operational performance and drive stockholder value creation. In connection with the 2024 Plan, which is expected to be substantially completed by the end of 2025, the Company anticipates a net reduction in the Company's global workforce of approximately 2% to 4%. The proposed changes are subject to co-determination processes with employee representative groups in countries where required. Actions taken under the 2024 Plan seek to further streamline the Company's operations and global footprint, as well as improve alignment of the Company's cost structure with its strategic growth objectives. As of September 30, 2025, the Company has incurred $30 million in restructuring charges under the 2024 Plan since its inception, primarily related to employee transition, severance payments and employee benefits, which are expected to be paid by the end of 2025. Remaining restructuring charges attributable to the 2024 Plan are not expected to be material.

With the restructuring plan approved by the Board of Directors of the Company on February 14, 2023 (the "2023 Plan"), the Company sought to restructure the business through a new operating model with five global business units, optimize central functions and overall management infrastructure, and implement other efforts aimed at cost savings. The 2023 Plan's annual cost savings target of $200 million has been substantially met, with the benefits mostly offset in the short term by additional investments in sales personnel, the Company's new global Enterprise Resource Planning ("ERP") system, and other transformation initiatives. As of September 30, 2025, the Company has incurred $86 million in restructuring charges under the 2023 Plan since its inception, primarily related to employee transition, severance payments, employee benefits, and facility closure costs, and $20 million in other non-recurring costs related to restructuring activities, which mostly consist of consulting, legal, and other professional service fees. Remaining restructuring charges attributable to the 2023 Plan are not expected to be material.

------

The liabilities associated with the Company's restructuring plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company's restructuring accruals at September 30, 2025 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Severance | Severance | Severance | Severance |
| (in millions) | 2023 and Prior Plans | 2024 Plans | Other Actions | Total |
| Balance at December 31, 2024 | $13 | $19 | $— | $32 |
| &nbsp;&nbsp;Provisions | 1 | 3 | 13 | 17 |
| &nbsp;&nbsp;Amounts applied | (11) | (18) | (4) | (33) |
| &nbsp;&nbsp;Change in estimates | (2) | (1) |  | (3) |
| Balance at September 30, 2025 | $1 | $3 | $9 | $13 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Other Restructuring Costs | Other Restructuring Costs | Other Restructuring Costs | Other Restructuring Costs |
| (in millions) | 2023 and Prior Plans | 2024 Plans | Other Actions | Total |
| Balance at December 31, 2024 | $1 | $— | $— | $1 |
| &nbsp;&nbsp;Provisions | 1 |  | 1 | 2 |
| &nbsp;&nbsp;Amounts applied | (2) |  |  | (2) |
| Balance at September 30, 2025 | $— | $— | $1 | $1 |

---

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (in millions) | December 31, 2024 | Provisions | Amounts<br>Applied | Change in Estimates | September 30, 2025 |
| Connected Technology Solutions | $9 | $4 | $(9) | $(2) | $2 |
| Essential Dental Solutions | 11 | 1 | (9) | (1) | 2 |
| Orthodontic and Implant Solutions | 9 | 5 | (8) |  | 6 |
| Wellspect Healthcare | 3 | 1 | (2) |  | 2 |
| All Other | 1 | 8 | (7) |  | 2 |
| &nbsp;&nbsp;Total | $33 | $19 | $(35) | $(3) | $14 |

---

**NOTE 9 – FINANCIAL INSTRUMENTS AND DERIVATIVES**

**Derivative Instruments and Hedging Activities**

The Company's business activities and operations expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company's operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes.

The following summarizes the notional amounts of hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at September 30, 2025 and the notional amounts expected to mature during the next 12 months.

------

---

| | | |
|:---|:---|:---|
| **(in millions)** | Aggregate Notional Amount | Aggregate Notional Amount Maturing within 12 Months |
| **Hedges of Net Investments** |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $870 | $345 |
| &nbsp;&nbsp;Cross currency basis swaps | 1413 |  |
| Total derivative instruments designated as hedges of net investments | $2283 | $345 |
| **Fair Value Hedges** |  |  |
| &nbsp;&nbsp;Interest rate swaps | $150 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts |  |  |
| Total derivative instruments designated as fair value hedges | $150 | $— |
| **Derivative Instruments not Designated as Hedges** |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $773 | $773 |
| Total derivative instruments not designated as hedges | $773 | $773 |

---

**Cash Flow Hedges**

<u>Interest Rate Risk Management</u>

The Company enters into interest rate swap contracts to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

On May 26, 2020, the Company paid $31 million to settle the $150 million notional Treasury rate lock contract, which partially hedged the interest rate risk of the $750 million Senior Notes due June 2030. This loss is amortized over the ten-year life of the notes. As of September 30, 2025 and December 31, 2024, $14 million and $16 million, respectively, of this loss is remaining to be amortized from AOCI in future periods.

<u>AOCI Release</u>

Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At September 30, 2025, the Company expects to reclassify $3 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI, see Note 4, Comprehensive Loss.

**Hedges of Net Investments in Foreign Operations &nbsp;&nbsp;&nbsp;&nbsp;**

The Company has significant investments in foreign subsidiaries, the net assets of which are exposed to volatility in foreign currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of these exposures. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments, and the intrinsic value changes in these instruments are recorded on AOCI, net of tax effects. The time-value component of the fair value of the derivative instrument is amortized on a straight-line basis in Other income in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows, except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign currency exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

------

**Fair Value Hedges**

<u>Interest Rate Risk Management</u>

On February 13, 2024, the Company paid $9 million to settle the variable interest rate swap with a notional amount of $100 million which was originally set to mature on June 1, 2026. This closure of the interest rate swap will result in a loss of $8 million being amortized over the remaining life of the Senior Notes due June 2030.

**Derivative Instruments Not Designated as Hedges**

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other income in the Consolidated Statements of Operations. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

**Derivative Instrument Activity**

The effect of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, |
| | 2025 | 2025 | 2024 | 2024 |
| (in millions) | Interest expense, net | Other income | Interest expense, net | Other income |
| **Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded** | $23 | $(11) | $18 | $(2) |
| **(Gain) loss on Cash Flow Hedges reclassified from AOCI into income** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $— | $— | $— | $— |
| **(Gain) loss on Hedges of Net Investment** |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $— | $(11) | $— | $(1) |
| &nbsp;&nbsp;Foreign exchange forward contracts |  | (7) |  | (6) |
| **(Gain) loss on Fair Value Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $3 | $— | $2 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts |  |  |  |  |
| **(Gain) loss on Derivative Instruments not Designated as Hedges** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $— | $1 | $— | $— |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Amount of Gain or (Loss) Recognized in AOCI | Amount of Gain or (Loss) Recognized in AOCI | | Amount of Gain or (Loss) Reclassified from AOCI into Income | Amount of Gain or (Loss) Reclassified from AOCI into Income |
| | Three Months Ended September 30, | Three Months Ended September 30, | Consolidated Statements of Operations Location | Three Months Ended September 30, | Three Months Ended September 30, |
| (in millions) | 2025 | 2024 | Consolidated Statements of Operations Location | 2025 | 2024 |
| **Hedges of Net Investments** |  |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $(36) | $(8) | Other expense (income), net | $— | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts | 7 | (38) | Other expense (income), net |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| | 2025 | 2025 | 2024 | 2024 |
| (in millions) | Interest expense, net | Other income | Interest expense, net | Other income |
| **Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded** | $66 | $(10) | $53 | $(10) |
| **(Gain) loss on Cash Flow Hedges reclassified from AOCI into income** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $2 | $— | $2 | $— |
| **(Gain) loss on Hedges of Net Investment** |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $— | $(13) | $— | $(3) |
| &nbsp;&nbsp;Foreign exchange forward contracts |  | (19) |  | (19) |
| **(Gain) loss on Fair Value Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $5 | $— | $6 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts |  |  |  |  |
| **(Gain) loss on Derivative Instruments not Designated as Hedges** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $— | $13 | $— | $— |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Amount of Gain or (Loss) Recognized in AOCI | Amount of Gain or (Loss) Recognized in AOCI | | Amount of Gain or (Loss) Reclassified from AOCI into Income | Amount of Gain or (Loss) Reclassified from AOCI into Income |
| | Nine Months Ended September 30, | Nine Months Ended September 30, | Consolidated Statements of Operations Location | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | Consolidated Statements of Operations Location | 2025 | 2024 |
| **Cash Flow Hedges** |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $— | $— | Cost of products sold | $— | $— |
| &nbsp;&nbsp;Interest rate swaps |  |  | Interest expense, net | (2) | 2 |
| **Hedges of Net Investments** |  |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $(65) | $— | Other expense (income), net | $— | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts | (100) | (5) | Other expense (income), net |  |  |

---

------

**Consolidated Balance Sheets Location of Derivative Fair Values**

The fair value and the financial statement presentation of the Company's derivatives in the Consolidated Balance Sheets were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | September 30, 2025 | September 30, 2025 | September 30, 2025 | September 30, 2025 |
| (in millions) | Prepaid Expenses and Other Current Assets | Other Noncurrent Assets | Accrued Liabilities | Other Noncurrent Liabilities |
| **Designated as Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $— | $— | $24 | $44 |
| &nbsp;&nbsp;Interest rate swaps |  |  | 5 | 9 |
| &nbsp;&nbsp;Cross currency basis swaps | 41 |  |  | 88 |
| Total | $41 | $— | $29 | $141 |
| **Not Designated as Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $4 | $— | $9 | $— |
| Total | $4 | $— | $9 | $— |
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
| (in millions) | Prepaid Expenses and Other Current Assets | Other Noncurrent Assets | Accrued Liabilities | Other Noncurrent Liabilities |
| **Designated as Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $5 | $9 | $— | $1 |
| &nbsp;&nbsp;Interest rate swaps |  |  | 4 | 17 |
| &nbsp;&nbsp;Cross currency basis swaps | 4 | 14 |  |  |
| Total | $9 | $23 | $4 | $18 |
| **Not Designated as Hedges:** |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $4 | $— | $8 | $— |
| Total | $4 | $— | $8 | $— |

---

**Balance Sheet Offsetting**

Substantially all of the Company's derivative contracts are subject to netting arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

------

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2025 were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | | Gross Amounts Not Offset in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | |
| (in millions) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received/Pledged | Net Amount |
| **Assets** |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $4 | $— | $4 | $(4) | $— | $— |
| &nbsp;&nbsp;Cross currency basis swaps | 41 |  | 41 | (41) |  |  |
| Total assets | $45 | $— | $45 | $(45) | $— | $— |
| **Liabilities** |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $77 | $— | $77 | $(14) | $— | $63 |
| &nbsp;&nbsp;Interest rate swaps | 14 |  | 14 |  |  | 14 |
| &nbsp;&nbsp;Cross currency basis swaps | 88 |  | 88 | (31) |  | 57 |
| Total liabilities | $179 | $— | $179 | $(45) | $— | $134 |

---

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2024 were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | | Gross Amounts Not Offset in the Consolidated Balance Sheets | Gross Amounts Not Offset in the Consolidated Balance Sheets | |
| (in millions) | Gross Amounts Recognized | Gross Amount Offset in the Consolidated Balance Sheets | Net Amounts Presented in the Consolidated Balance Sheets | Financial Instruments | Cash Collateral Received/Pledged | Net Amount |
| **Assets** |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $18 | $— | $18 | $(5) | $— | $13 |
| &nbsp;&nbsp;Cross currency basis swaps | 18 |  | 18 | (6) |  | 12 |
| Total assets | $36 | $— | $36 | $(11) | $— | $25 |
| **Liabilities** |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | $9 | $— | $9 | $(4) | $— | $5 |
| &nbsp;&nbsp;Interest rate swaps | 21 |  | 21 | (7) |  | 14 |
| Total liabilities | $30 | $— | $30 | $(11) | $— | $19 |

---

------

**NOTE 10 – FAIR VALUE MEASUREMENT**

The estimated fair and carrying values of the Company's total debt were $2,334 million and $2,395 million, respectively, at September 30, 2025. At December 31, 2024, the estimated fair and carrying values were $2,037 million and $2,135 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at September 30, 2025 and December 31, 2024 and interest rates for companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.

<u>Assets and liabilities measured at fair value on a recurring basis</u>

The Company's financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | September 30, 2025 | September 30, 2025 | September 30, 2025 | September 30, 2025 |
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
| **Assets** |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $41 | $— | $41 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts | $4 | $— | $4 | $— |
| Total assets | $45 | $— | $45 | $— |
| **Liabilities** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $14 | $— | $14 | $— |
| &nbsp;&nbsp;Cross currency basis swaps | 88 |  | 88 |  |
| &nbsp;&nbsp;Foreign exchange forward contracts | 77 |  | 77 |  |
| Total liabilities | $179 | $— | $179 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
| (in millions) | Total | Level 1 | Level 2 | Level 3 |
| **Assets** |  |  |  |  |
| &nbsp;&nbsp;Cross currency basis swaps | $18 | $— | $18 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts | 18 |  | 18 |  |
| Total assets | $36 | $— | $36 | $— |
| **Liabilities** |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $21 | $— | $21 | $— |
| &nbsp;&nbsp;Foreign exchange forward contracts | 9 |  | 9 |  |
| &nbsp;&nbsp;Contingent consideration on acquisitions | 4 |  |  | 4 |
| Total liabilities | $34 | $— | $30 | $4 |

---

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks.

There were no transfers between fair value measurement levels during the nine months ended September 30, 2025.

------

**NOTE 11 – INCOME TAXES**

The effective tax rates for the three months ended September 30, 2025 and 2024 were (86.5%) and (3.3%), respectively. For the nine months ended September 30, 2025 and 2024 the rates were (33.6%) and (16.7%), respectively. The decrease in effective tax rate is primarily driven by intangible and goodwill impairment.

**NOTE 12 – FINANCING ARRANGEMENTS**

The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $700 million, that expires on May 12, 2028. The Company also has a $700 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $700 million as the total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had no outstanding borrowings under the commercial paper facility at September 30, 2025 and $410 million in outstanding borrowings under the commercial paper facility at December 31, 2024, and the Company had no outstanding borrowings under the multi-currency revolving credit facility at September 30, 2025 and December 31, 2024. The Company also has access to $42 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by other outstanding short-term borrowings of $5 million.

On March 19, 2025, the Company entered into a 364-day term loan of $435 million with a maturity date of March 18, 2026 (the "Bridge Loan Facility"). The proceeds were $432 million, net of issuance fees totaling $3 million. The net proceeds from the Bridge Loan Facility were used to repay indebtedness under the Company's commercial paper facility and pre-fund repayment of certain other short-term indebtedness. Subsequently, on June 12, 2025, the Company issued $550 million aggregate principal amount of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 (the "Notes") through a public offering. The proceeds from the sale of the Notes were $545 million after deduction of underwriters' fees. On June 12, 2025, the Company used a portion of these proceeds to repay in full the outstanding principal and accrued interest due under the Bridge Loan Facility, which was then terminated as a result of the repayment. The Company intends to use the remaining proceeds from the sale of the Notes for general corporate purposes.

At September 30, 2025, the weighted-average interest rate for short-term debt was 4.9%.

At September 30, 2025, the Company had $736 million of borrowings available under lines of credit, including lines available under its short-term arrangements and revolving credit facility.

The Company's revolving credit facility and senior notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. On June 3, 2025, the Company entered into agreements with the applicable noteholders to amend certain provisions of its private placement notes and also obtained the consent of the requisite lenders under its revolving credit facility to amend certain provisions of that credit agreement. Under the amended terms, the Company and the relevant counterparties agreed to, among other things: (i) establish a financial covenant requiring that the ratio of senior debt to capitalization shall not exceed 0.6, (ii) increase the maximum allowable consolidated leverage ratio to 0.65, (iii) adjust the German subsidiary debt to be treated as permitted debt under a newly designated standalone basket, and (iv) implement provisions governing interest rate adjustments in the event that the Company's credit rating is downgraded below investment grade. At September 30, 2025, the Company was in compliance with the aforementioned provisions.

Interest expense, net includes interest income of $3 million and $5 million for the three months ended September 30, 2025 and 2024, respectively. Interest expense, net includes interest income of $10 million and $15 million for the nine months ended September 30, 2025 and 2024, respectively. Interest income primarily relates to interest-bearing cash equivalents.

**NOTE 13 – GOODWILL AND INTANGIBLE ASSETS**

The Company's policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate a given asset might be impaired. For the goodwill impairment tests as of April 1, 2025, the Company utilized an income-based approach for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment and performed a qualitative assessment for the other two reporting units with goodwill balances, due to the significant excess of fair value over carrying value for those units.

As a result of the annual goodwill impairment test, the Company determined that the fair value of the Implant & Prosthetic Solutions reporting unit was below its carrying value. Fair value was determined using a discounted cash flow model based on

------

inputs developed from internal and market-based data, including ten-year forecasted cash flows plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. The Company's significant assumptions in the discounted cash flow model included, but were not limited to, a discount rate of 12.5%, revenue growth rates (including perpetual growth rates), operating margin percentages, and net working capital changes of the reporting unit's business. The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was primarily driven by the impact of tariffs and lower projected volumes, due partly to competitive pressures, particularly in the United States and European markets. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term. As a result of this test, the Company recorded a pre-tax goodwill impairment charge as of June 30, 2025 of $156 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment, which was recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations. Based on the qualitative assessment performed for the other reporting units, the Company believed there was no indication that the carrying value more likely than not exceeded the fair value in each case as of April 1, 2025.

Indefinite-lived intangible assets were assessed either through a computation of fair value using an income approach, specifically a relief from royalty method for acquired trade names and trademarks, or through a qualitative assessment for in-process research and development ("R&D"). The Company's significant assumptions in the relief from royalty method included, but were not limited to, discount rates (ranging from 11.0% to 15.0%), revenue growth rates (including perpetual growth rates) and royalty rates, all of which were determined using the judgment of management. Other assumptions were consistent with those applied to goodwill impairment testing. These assumptions for both the goodwill and indefinite-lived intangible asset tests were developed in consideration of current market conditions and future expectations which included, but were not limited to, impact from competition and new product developments. In conjunction with this annual test, the Company identified impairments of certain indefinite-lived intangible assets including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The decline in fair value of the trade names and trademarks was driven by the impact of tariffs, which reduced the royalty rates used to value these assets, and lower volumes for the Company's equipment and implant products due partly to competitive pressure, which contributed to reduced forecasted revenues. As a result of this test, the Company recorded pre-tax charges of $79 million to intangible assets as of June 30, 2025, consisting of $64 million within the Connected Technology Solutions segment and $15 million within the Implant & Prosthetic Solutions reporting unit, which were recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

For the three months ended September 30, 2025, the Company considered additional qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in indicators of additional impairment of goodwill or indefinite-lived intangible assets. Due to the lower-than-expected results for Implant & Prosthetic Solutions, it was determined that the fair value of this reporting unit had declined below its carrying value. The updated fair value was computed in a manner consistent with the annual test described above, with the decline primarily driven by lower-than-expected volumes, particularly in the United States, and the impact of tariffs. As a result of the updated impairment testing, as of September 30, 2025, the Company recorded a pre-tax goodwill impairment charge of $253 million for the Implant & Prosthetic Solutions reporting unit. Additionally, review of the indefinite-lived intangible assets previously impaired as of June 30, 2025, using a consistent methodology as that which was used for the annual test, indicated a further decline in fair value as of September 30, 2025 due to lower volumes for the Company's equipment and implant products. As a result, the Company recorded indefinite-lived intangible asset pre-tax impairment charges of $4 million and $5 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2025.

Following these impairments, the fair values of the Implant & Prosthetic Solutions reporting unit and the abovementioned indefinite-lived intangible assets continued to approximate their carrying values as of September 30, 2025. Any further decline in key assumptions, such as an increase in the discount rate by 50 basis points or further reduction in projected revenues or margins, would likely lead to additional material impairments of the Implant & Prosthetic Solutions reporting unit, the above-mentioned intangible assets, or both. Additionally, the fair value of other assets within the Connected Technology Solutions segment, including fixed assets and definite-lived intangible assets, may be at risk of material impairment if forecasted revenues or margins for this business decline further, or if the Company is not able to adequately mitigate the impact of tariff costs in future years. Remaining goodwill associated with the Implant & Prosthetic Solutions reporting unit was $123 million as of September 30, 2025, which represents all remaining goodwill within the Orthodontic and Implant Solutions segment. The remaining carrying values of the indefinite-lived intangible assets within the Connected Technology Solutions and Orthodontic and Implant Solutions segments approximate fair value and were $105 million and $90 million, respectively, as of September 30, 2025.

------

There is a risk of future impairment charges if there is a decline in the fair value of the reporting units or indefinite-lived intangible assets as a result of, among other things, actual financial results that are lower than forecasts, an adverse change in valuation assumptions, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets. There can be no assurance that the Company's future asset impairment testing will not result in a material charge to earnings.

A reconciliation of changes in the Company's goodwill by reportable segment is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| (in millions) | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total |
| Balance at December 31, 2024 |  |  |  |  |  |
| &nbsp;&nbsp;Goodwill | $291 | $829 | $1276 | $265 | $2661 |
| &nbsp;&nbsp;Accumulated impairment losses | (291) |  | (773) |  | (1064) |
| Goodwill, net at December 31, 2024 |  | 829 | 503 | 265 | 1597 |
| Impairment |  |  | (409) |  | (409) |
| Foreign Currency Translation |  | 29 | 29 | 24 | 82 |
| Balance at September 30, 2025 |  |  |  |  |  |
| &nbsp;&nbsp;Goodwill | $291 | $858 | $1305 | $289 | $2743 |
| &nbsp;&nbsp;Accumulated impairment losses | $(291) | $— | $(1182) | $— | $(1473) |
| Goodwill, net at September 30, 2025 | $— | $858 | $123 | $289 | $1270 |

---

Identifiable definite-lived and indefinite-lived intangible assets were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | September 30, 2025 | September 30, 2025 | September 30, 2025 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
| (in millions) | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net<br>Carrying<br>Amount | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net<br>Carrying<br>Amount |
| &nbsp;&nbsp;Developed technology and patents | $1782 | $(1296) | $486 | $1639 | $(1079) | $560 |
| &nbsp;&nbsp;Trade names and trademarks | 84 | (78) | 6 | 79 | (73) | 6 |
| &nbsp;&nbsp;Licensing agreements | 42 | (29) | 13 | 29 | (28) | 1 |
| &nbsp;&nbsp;Customer relationships | 1098 | (829) | 269 | 1019 | (716) | 303 |
| Total definite-lived | 3006 | (2232) | 774 | 2766 | (1896) | 870 |
| &nbsp;&nbsp;Indefinite-lived trade names and trademarks | $286 | $— | $286 | $332 | $— | $332 |
| &nbsp;&nbsp;In-process R&D | 5 |  | 5 | 5 |  | 5 |
| Total indefinite-lived | 291 |  | 291 | 337 |  | 337 |
| Total identifiable intangible assets | $3297 | $(2232) | $1065 | $3103 | $(1896) | $1207 |

---

In the nine months ended September 30, 2025, the Company acquired naming and certain other rights to a university dental laboratory in exchange for $14 million of equipment and consumable products to be transferred to the university through 2040. These rights were recorded as an intangible asset to be amortized over a fifteen-year period, with an offsetting contract liability that will be relieved as the equipment and products are provided to the university.

------

**NOTE 14 – COMMITMENTS AND CONTINGENCIES**

<u>Contingencies</u>

On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York (the "EDNY Court") against the Company and certain individual defendants. The case was narrowed following its inception. The plaintiff's claims which, as discussed below, have now been approved for final settlement, were that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. ("Sirona") with DENTSPLY International Inc. (the "Merger") and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleged that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserted claims on behalf of a putative class consisting of all purchasers of the Company's stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, with briefing on the motion fully submitted on May 21, 2021. The Company's motion to dismiss was denied in a ruling by the EDNY Court on March 29, 2023, and the Company's answer to the second amended complaint was filed on May 12, 2023. Following additional motion practice—which remained outstanding with the EDNY Court—and discovery, the parties engaged in settlement discussions with the assistance of a mediator, and, in January 2025, reached a settlement in principle to resolve the case in full for $84 million. In connection with the settlement, the Company received an offsetting insurance policy receivable of approximately $78 million and paid the rest in cash. The excess of the settlement liability over the corresponding insurance policy receivable resulted in $6 million of legal expense which was recorded during the year ended December 31, 2024. The settlement agreement, which was negotiated and signed in January, was approved by the EDNY Court following a final approval hearing held on September 10, 2025.

On June 2, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees' & Sanitation Employees' Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371, and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of New York (the "SDNY Court") captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the "Securities Litigation"). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company's former Chief Executive Officer, and Mr. Jorge Gomez, the Company's former Chief Financial Officer, violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognized revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the SDNY Court. On June 1, 2023, the SDNY Court consolidated the two separate actions under case No. 1:22-cv-06339 and appointed as lead plaintiffs for the putative class the City of Birmingham Retirement and Relief System, the El Paso Firemen & Policemen's Pension Fund, and the Wayne County Employees' Retirement System (collectively, the "Lead Plaintiffs"). Lead Plaintiffs filed an amended class action complaint on July 28, 2023 (the "Amended Complaint"). In addition to asserting the same claims against the Company, Mr. Casey, and Mr. Gomez, the Amended Complaint added the Company's former Chief Accounting Officer, Mr. Ranjit S. Chadha, as a defendant (collectively, "Defendants"). On October 10, 2023, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiffs opposed the motion. On May 1, 2024, the SDNY Court granted the motion to dismiss as to Mr. Chadha and granted in part and denied in part the motion to dismiss as to the Company, Mr. Casey, and Mr. Gomez. The Company's answer to the Amended Complaint was filed on May 21, 2024. On November 15, 2024, Lead Plaintiffs filed a motion to certify the matter as a class action, to appoint Lead Plaintiffs as class representatives, and to appoint class counsel. Defendants opposed the motion. On July 10, 2025, the SDNY Court granted Lead Plaintiffs' motion for class certification, appointed the Lead Plaintiffs as class representatives, and appointed counsel for Lead Plaintiffs as class counsel. The Company has recognized a liability as of September 30, 2025, with an offsetting insurance receivable, resulting in no impact to the Consolidated Statements of Operations in the three and nine months ended September 30, 2025.

In addition to the Securities Litigation, as previously disclosed, the Company voluntarily contacted the SEC following the Company's announcement on May 10, 2022 of the internal investigation by the Audit and Finance Committee of the Company's Board of Directors. On October 14, 2025, the Company announced that the Division of Enforcement of the SEC has concluded its investigation of the Company and does not intend to recommend any enforcement action against the Company.

------

Separately, on July 13, 2023, Company stockholder George Presura filed a stockholder derivative suit in the Delaware Court of Chancery captioned George Presura, Derivatively on Behalf of Nominal Defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona, Inc., No. 2023-0708-NAC (the "Presura Derivative Litigation"). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Securities Litigation, and it alleges that during the period from June 9, 2021 through July 13, 2023, various of the defendants breached fiduciary duties, committed corporate waste, and misappropriated information to conduct insider trading by making materially false and misleading statements or omissions regarding the Company's recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On August 4, 2023, the Delaware Court of Chancery stayed the Presura Derivative Litigation until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation.

Additionally, on March 26, 2024, Company stockholder Calvin Snee filed a stockholder derivative suit in the Delaware Court of Chancery captioned Calvin Snee, derivatively on behalf of Dentsply Sirona Inc. v. Donald M. Casey Jr., et al. and Dentsply Sirona Inc, No. 2024-0308 (the "Snee Derivative Litigation"). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Presura Derivative Litigation and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company's recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.

On May 2, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Presura Derivative Litigation and Snee Derivative Litigation.

On July 19, 2024, Company stockholder Frank Manfre filed a stockholder derivative suit in the Delaware Court of Chancery captioned Frank Manfre, derivatively on behalf of nominal defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona Inc., No. 2024-0763 (the "Manfre Derivative Litigation"). The complaint asserts claims against current and former members of the Company's Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The complaint in this case contains allegations similar to those in the Snee Derivative Litigation, the Presura Derivative Litigation, and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company's recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.

On September 19, 2024, the Delaware Court of Chancery issued an order consolidating and staying the Manfre Derivative Litigation, Presura Derivative Litigation, and Snee Derivative Litigation.

On November 26, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned North Collier Fire Control and Rescue District Firefighters' Retirement Plan v. Dentsply Sirona Inc., et al., No. 1:24-cv-09083 (the "North Collier Action"). On December 18, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Calvin v. Dentsply Sirona Inc., et al., No. 1:24-cv-09764 (the "Calvin Action"), and on December 19, 2024, the Company was named as a defendant in a putative class action filed in the SDNY Court captioned Key West Police & Fire Pension Fund v. Dentsply Sirona Inc., et al., No. 1:24-cv-09819 (the "Key West Action"). The complaints in these three cases allege that, for different alleged class periods over the period from May 6, 2021 through November 6, 2024, the Company and certain current and former officers violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the performance of the Company's Byte aligners business, following the Company's acquisition of Byte LLC in December 2020. On February 21, 2025, the SDNY Court entered an order consolidating the North Collier Action, the Calvin Action, and the Key West Action under the caption In re Dentsply Sirona, Inc. Securities Litigation, No. 24-cv-9083 (the "2024 Securities Litigation"), and appointed lead plaintiffs and lead counsel for the consolidated case. An amended complaint was filed on May 9, 2025. On July 8, 2025, the Company and certain current and former officers of the Company filed a motion to dismiss the amended complaint.

Separately, on March 18, 2025, Company stockholder Kevin O'Connor filed a stockholder derivative suit in the SDNY Court captioned Kevin O'Connor, derivatively on behalf of Dentsply Sirona Inc. v. Simon D. Campion, et al. and Dentsply Sirona Inc., No. 1:25-cv-02246 (the "O'Connor Derivative Litigation"). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former

------

executive officers. The derivative complaint in this case contains allegations similar to those in the 2024 Securities Litigation, and it alleges that during the period from December 1, 2022 through November 6, 2024, various of the defendants breached fiduciary duties by, among other things, causing or allowing the Company to issue or make materially false and misleading statements concerning the Company's financial condition and business operations as related to the acquisition of Byte LLC.

Additionally, on April 9, 2025, Company stockholder William Andreotti filed a stockholder derivative suit in the SDNY Court captioned William Andreotti, Derivatively on Behalf of Dentsply Sirona, Inc. v. Simon D. Campion, et al. and Dentsply Sirona, Inc., No. 1:25-cv-02931 (the "Andreotti Derivative Litigation"). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former executive officers. The derivative complaint in this case contains allegations similar to those in the O'Connor Derivative Litigation and the 2024 Securities Litigation, and it alleges that beginning on December 1, 2022, various of the defendants breached fiduciary duties and were unjustly enriched by disseminating or approving materially false and misleading statements or omissions related to the acquisition of Byte LLC.

On April 29, 2025, the SDNY Court issued an order consolidating and staying the O'Connor Derivative Litigation and the Andreotti Derivative Litigation.

On March 21, 2023, Mr. Carlo Gobbetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l. ("DSI"), Italy, a wholly owned subsidiary of the Company, seeking a total of €28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the "SPA"), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobbetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now DSI). Under the SPA, a portion of the purchase price equal to €7 million was required to be deposited into an escrow account (the "Escrow Account") and released to Mr. Gobbetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. In connection with the closing of the share purchase transaction, the SPA was supplemented by a Facility Agreement, also dated October 8, 2012 (the "FA"), which specifically set out the mechanics of payment and release of the proceeds of the Escrow Account. The Austrian notary public, Mr. Gottfried Schachinger, acting as escrow agent, Mr. Gobbetti, and SIRONA Holdings GmbH, an affiliate of Sirona Dental Systems, Inc. which paid the €7 million into the Escrow Account, were parties to the FA. The FA is subject to Austrian law and to the jurisdiction of the Court of Salzburg in Austria.

Mr. Gobbetti claims that he is entitled to receive the €7 million outstanding balance of the purchase price under the SPA, plus €21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobbetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. On May 15, 2023, DSI filed its initial statement of defense denying that Mr. Gobbetti and the other sellers were entitled to receive the funds deposited in the Escrow Account and further disputing the allegations. Following the constitution of the arbitral tribunal, hearings were held on September 13, 2023 and January 19, 2024, to illustrate and discuss the positions of the parties. The parties also developed their arguments in several rounds of defensive briefs. The final submissions were completed on April 15, 2024, and the final hearing for discussion took place on May 8, 2024. On July 22, 2024, the arbitral tribunal rejected all of Mr. Gobbetti's claims, ruling that the Company had met its contractual obligations under the SPA, particularly regarding the balance of the purchase price. The arbitral tribunal also dismissed Mr. Gobbetti's claims in tort and those pertaining to the FA for lack of jurisdiction and lack of capacity for the Company to be sued. The arbitral tribunal observed that such claims should have been brought against SIRONA Holdings GmbH, which is a party to the FA but not to the SPA, before the Court of Salzburg in Austria based on the jurisdictional clause of the FA.

Mr. Gobbetti appealed the ruling of the arbitral tribunal on December 2, 2024 before the Court of Appeals of Milan, Italy (the "Court of Appeals") arguing that the ruling is null and void. According to Mr. Gobbetti, the arbitral tribunal did not grant him appropriate defense rights under the Italian Civil Code and did not fully address the merits of his claims, despite acknowledging jurisdiction. Mr. Gobbetti asked the Court of Appeals to directly sentence DSI to pay the €7 million, plus damages of €21 million and interest accruing until the time of payment. On April 17, 2025, DSI filed its statement of defense, asking the Court of Appeals to reject Mr. Gobbetti's appeal and confirm the arbitral award in its entirety. The first hearing in the appeal proceedings took place on May 7, 2025, and the Court of Appeals concluded that there was no need to take additional evidence. A final hearing is scheduled for February 11, 2026.

Except as noted above, no specific amounts of damages have been alleged in these lawsuits. The Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be

------

significant. The Company intends to defend these lawsuits vigorously, although the Company may elect to settle certain litigation matters, but there can be no assurance that the Company will be successful in any defense or that matters can be settled on terms favorable to the Company. If any of the lawsuits are decided adversely, the Company may be liable for significant damages directly or under its indemnification obligations, which could adversely affect the Company's business, results of operations and cash flows. At this stage, the Company has accrued losses which are deemed probable, along with related insurance receivables, but the Company is unable to assess whether any incremental material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.

The Internal Revenue Service ("IRS") is conducting an examination of the Company's U.S. federal income tax returns for the tax years 2015 and 2016. The Company received a Notice of Proposed Adjustment in April 2023 and a Revenue Agent Report in January 2024 from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax liability for the internal reorganization, if sustained, the proposed adjustment would result in the Company owing additional federal income taxes on a distribution of $451 million related to a stock redemption that occurred after the internal reorganization was completed in 2016. The proposed adjustment, if sustained, would also result in a loss of foreign tax credits carried forward to later tax years. The Company believes that it accurately reported the federal income tax consequences of the internal restructuring and stock redemption in its tax returns and in April 2024, submitted an administrative protest with the IRS Independent Office of Appeals contesting the examination team's proposed adjustments. The IRS examination team provided the Company with a rebuttal to the Company's administrative protest during August 2024 and informed the Company that the dispute would be forwarded to the IRS Independent Office of Appeals.

The General Public Prosecutor's Office Frankfurt am Main is investigating a series of intercompany loans implemented in 2016 and 2017 as part of the post-merger integration activities of DENTSPLY International Inc. and Sirona Dental Systems, Inc. The Company is cooperating with the investigation. The Company believes that the transactions at issue complied with all applicable German laws. No charges have been filed against the Company or any individuals.

The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters and believes it is more likely than not that its positions will be sustained, although the Company may elect to settle certain matters. Unless otherwise disclosed herein, the Company has not accrued losses for these matters because the Company does not believe the risk of loss is probable and cannot estimate the range of any potential loss with any reasonable degree of accuracy.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company's products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition, sales, and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory, damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company's experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company's business, financial condition, results of operations, or liquidity.

While the Company maintains general, product, property, workers' compensation, automobile, cargo, aviation, crime, fiduciary, cyber, and directors' and officers' liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

------

<u>Commitments</u>

*Purchase Commitments*

The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At September 30, 2025, non-cancelable purchase commitments were as follows:

---

| | |
|:---|:---|
| (in millions) |  |
| 2025 | $46 |
| 2026 | 135 |
| 2027 | 69 |
| 2028 | 36 |
| 2029 | 2 |
| Thereafter |  |
| Total | $288 |

---

The above information should be read in conjunction with Part II, Item 7 "Contractual Obligations" and Part II, Item 8, Note 21, Commitments and Contingencies, in the 2024 Form 10-K.

The table above includes commitments with a cloud services provider supporting the Company's digital platform which requires minimum cumulative purchases totaling $69 million through 2028.

*Indemnification*

In the normal course of business to facilitate sales of the Company's products and services, the Company indemnifies certain parties, including customers, vendors, lessors, services providers, and others, with respect to certain matters, including, but not limited to, services to be provided by or for the Company, and intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its current and former directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.

It is not possible to make a reasonable estimate of the maximum potential amount of indemnification under these indemnification agreements due to the unique facts and circumstances involved in the various matters which give rise to indemnification claims and the particular terms of each agreement. However, to the extent that valid indemnification claims arise in the future, future payments by the Company could be significant and could have a material adverse effect on the Company's results of operations or cash flows in a particular period.

------

**DENTSPLY SIRONA Inc. and Subsidiaries**

**Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations**

Information included in or incorporated by reference in this Form 10-Q, and other filings with the SEC and the Company's press releases or other public statements, contains or may contain forward-looking statements. Please refer to the discussion under the header "Forward-Looking Statements and Associated Risks" in the forepart of this Form 10-Q.

**Company Profile**

DENTSPLY SIRONA Inc. is the world's largest diversified manufacturer of professional dental products and technologies, with a 138-year history of innovation and service to the dental industry and a vision of improving oral health and continence care globally. Dentsply Sirona develops, manufactures, and markets comprehensive solutions, including technologically advanced dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective, and connected solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona's worldwide headquarters is located in Charlotte, North Carolina, and its shares of common stock are listed in the United States on Nasdaq under the symbol XRAY.

**BUSINESS**

**Segment Descriptions**

<u>Connected Technology Solutions</u>

This segment includes the design, manufacture, and sales of the Company's dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories. Dental CAD/CAM technologies are products designed for dental professionals to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform.

<u>Essential Dental Solutions</u>

This segment includes the development, manufacture, and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.

<u>Orthodontic and Implant Solutions</u>

This segment includes the design, manufacture, and sales of the Company's various digital implant systems and innovative dental implant products, digital dentures and dental professional-directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.

<u>Wellspect Healthcare</u>

This segment includes the design, manufacture, and sales of the Company's innovative continence care solutions for both urinary and bowel management. Wellspect is one of the world's leading manufacturers of intermittent urinary catheters, with LoFric as its most known brand. To help those with chronic or severe constipation, Wellspect also offers an advanced irrigation system, Navina, which combines a high degree of user convenience, clinical effectiveness and connectivity into one smart system.

------

**The impact of global economic conditions**

Various headwinds are expected to weigh on global growth throughout the remainder of 2025, due in large part to increasing uncertainties related to global trade policies and inflation. Changes in trade policy, supply chain constraints, higher energy costs, labor shortages, and geopolitical tensions have all contributed to the risk of higher inflation and general economic uncertainty across the industry and the regions in which the Company operates. In recent years, the Company has experienced higher prices for certain raw materials, including electronic components, which have led to a negative impact on margins. The Company may not be successful in its efforts to fully mitigate or offset the impacts of cost inflation.

The challenging macroeconomic conditions have impacted consumer confidence, the ability and willingness of clinicians to obtain financing to purchase equipment, and consumer discretionary spending for elective procedures, leading to adverse impacts on the Company's results of operations, particularly in the United States. The Company has taken actions to attempt to mitigate the effects of challenging macroeconomic conditions and may take further actions in the future.

**Recent tariff policies**

As disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"), the Company's business is subject to risks related to, among other factors, tariffs and other trade protection measures put in the place by the United States and other countries. The U.S. government has implemented or is in the process of implementing various tariffs on the importation of goods from certain countries, a number of which are applicable to the Company's supply chain, operations, and sales, including a baseline 10% tariff on all foreign goods, a 15% tariff in lieu of the baseline tariff on goods from countries in the European Union, and higher incremental tariff rates on goods imported from other specified nations.

The tariffs enacted and proposed by the Trump Administration to date and retaliatory tariffs by other countries could make it significantly more difficult or costly for the Company to import certain products or materials to the United States, or export products or materials from the United States to other countries. Currently, a small portion of the products, materials, and components used in our products are imported from China, and a significant share of the dental equipment that we sell in the United States is manufactured in Europe. Europe is also a major market for our products, including certain consumable products made in the United States, while sales in China represent less than 5% of the Company's global sales on an annual basis. We continue to monitor and evaluate the ongoing and potential impacts of the tariffs and changes in trade policy, whether implemented or proposed, on our supply chain, costs, net sales and profitability. We have implemented and continue to evaluate additional strategies that would mitigate such impacts, including competitive pricing strategies to offset tariffs and evaluating potential sourcing options that work with our vendors and merchants to seek to minimize products sourced from high tariff rate countries, both for existing products and for new product development. The impact that these tariffs and changes in trade policy will ultimately have on our financial results remains uncertain, including the impact on demand for our products in certain markets if prices rise as a consequence of import tariffs. For additional information, see Part I, Item 1A, "Risk Factors" in our 2024 Form 10-K.

**The impact of geopolitical conflicts**

Geopolitical conflicts are expected to continue to shape market dynamics and pose general threats to financial stability in affected regions, including ongoing tensions from both the Russia-Ukraine conflict and the conflict in the Middle East. Overall, the Company's operations in Russia, Ukraine, and Israel have not been materially impacted by these conflicts.

The Company's operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one site in southern Israel, both of which remain open and continue to operate normally. For the nine months ended September 30, 2025, net sales of products produced at these sites comprised approximately 3% of our consolidated net sales and approximately 13% of the net sales of the Orthodontic and Implant Solutions segment. Net assets within Israel totaled $166 million as of September 30, 2025, consisting primarily of acquired technology, property, plant and equipment, cash, and inventory associated with our operations in the country.

In May 2024, in response to ongoing military actions by Israel in the Gaza strip, the government of Turkey implemented restrictions on the import of goods manufactured within Israel for sale in the Turkish market, which were still in effect as of September 30, 2025. Sales of our products made in Israel and sold in Turkey have historically represented approximately 1% of our global sales of the Implant & Prosthetic Solutions reporting unit, but this product category is an area of relatively high potential growth. The loss of sales to Turkey has been partially offset by sales of implants produced outside of Israel. It is not clear when these restrictions will be lifted or if other countries will institute similar restrictions.

------

In February 2022, because of the invasion of Ukraine by Russia, economic sanctions were imposed by the United States, the European Union, and certain other countries on Russian financial institutions and businesses. Due to the medical nature of our products, the current sanctions have not materially restricted our ability to continue selling many of our products to customers located in Russia. For the nine months ended September 30, 2025, net sales in Russia and Ukraine were approximately 3% of our consolidated net sales, and net assets in these countries were $91 million as of September 30, 2025. These net assets include $57 million of cash and cash equivalents held within Russia as of September 30, 2025, as well as inventory and trade accounts receivable. Due to currency control measures imposed by the Russian government, which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we continue to be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs. Additionally, beginning in September 2024, as a result of further restrictions by European financial institutions on receiving payments from Russia, our capacity to receive intercompany payments for the delivery of our products into Russia has been partially reduced, which further limits our ability to use cash received from sales in Russia for our general purposes.

**Distribution arrangements**

In July 2024, the Company delivered a one-year notice of non-renewal in connection with its non-exclusive distribution agreements with Patterson Companies, Inc. ("Patterson") for the distribution of dental equipment in the United States and Canada. The Company remains engaged in discussions for new distribution agreements with Patterson. It is anticipated that Patterson will continue to be one of the Company's largest distributors as a percentage of the Company's global revenue while negotiations continue. However, failure to successfully renegotiate the distribution agreements or secure potential new agreements with another distributor could have a material adverse effect on the Company's business, operating results and financial condition. For additional information, see Part I, Item 1A, "Risk Factors" in our 2024 Form 10-K.

**RESULTS OF OPERATIONS, THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 COMPARED TO THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024**

**Net Sales**

The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also presents changes in net sales on a constant currency basis, which is a Non-GAAP measure. The Company defines "constant currency" as the reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's currency exchange rates.

Constant currency is an important internal measure for the Company, and its senior management receives a monthly analysis of operating results that includes constant currency. The performance of the Company is measured on this metric along with other performance metrics.

The Company discloses changes in constant currency to allow investors to evaluate the performance of the Company's operations exclusive of the items listed above that may impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this supplemental information is helpful in understanding underlying net sales trends. Our measure of constant currency may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $904 | $951 | $(47) | (5.0%) | $2719 | $2888 | $(169) | (5.9%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable foreign exchange impact |  |  |  | 3.0% |  |  |  | 0.5% |
| **Constant currency** |  |  |  | (8.0%) |  |  |  | (6.4%) |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three and nine months ended September 30, 2025 was driven by lower volumes in the Orthodontic and Implant Solutions segment as a result of the suspension of Byte sales, as well as lower

------

volumes of CAD/CAM, implants, preventive, and restorative products, particularly in the United States. The decrease was partially offset by higher volumes of treatment centers, endodontic consumables, and Wellspect Healthcare products.

**Net Sales by Segment**

<u>Connected Technology Solutions</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $259 | $269 | $(10) | (3.9%) | $737 | $769 | $(32) | (4.1%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable (unfavorable) foreign exchange impact |  |  |  | 3.1% |  |  |  | 0.5% |
| **Constant currency** |  |  |  | (7.0%) |  |  |  | (4.6%) |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three and nine months ended September 30, 2025 was primarily due to lower volumes of CAD/CAM products, particularly in the United States, driven in part by competitive pressures including pricing. The decrease was partially offset by higher volumes of imaging and treatment center equipment in Europe and Rest of World.

<u>Essential Dental Solutions</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $357 | $369 | $(12) | (3.4%) | $1097 | $1108 | $(11) | (1.0%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable (unfavorable) foreign exchange impact |  |  |  | 2.8% |  |  |  | 0.5% |
| **Constant currency** |  |  |  | (6.2%) |  |  |  | (1.5%) |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three and nine months ended September 30, 2025 was primarily driven by lower sales of preventive and restorative products, due primarily to the higher volumes in the prior year comparative periods from a shift in the timing of distributor orders from the fourth quarter into the third quarter of 2024 on account of the Company's Enterprise Resource Planning ("ERP") system implementation in the United States. The decrease was partially offset by higher volumes of endodontic products in Europe and Rest of World.

<u>Orthodontic and Implant Solutions</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $205 | $241 | $(36) | (15.0%) | $648 | $788 | $(140) | (17.8%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable (unfavorable) foreign exchange impact |  |  |  | 2.1% |  |  |  | 0.3% |
| **Constant currency** |  |  |  | (17.1%) |  |  |  | (18.1%) |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three and nine months ended September 30, 2025 was driven by

------

lower volumes of clear aligners in the United States, primarily related to the suspension of Byte sales, as well as lower volumes for implants and prosthetics products in the United States and Rest of World. The decrease was partially offset by higher volumes of orthodontic products in Europe. Additionally, during the nine months ended September 30, 2025, the Company refined its estimate of expected customer refunds for the Byte aligner business, resulting in a $13 million adjustment that increased net sales.

<u>Wellspect Healthcare</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $83 | $72 | $11 | 15.6% | $237 | $223 | $14 | 6.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable foreign exchange impact |  |  |  | 6.3% |  |  |  | 1.8% |
| **Constant currency** |  |  |  | 9.3% |  |  |  | 4.7% |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales increase on a constant currency basis for the three and nine months ended September 30, 2025 was primarily due to higher volumes, partly as a result of new product launches.

**Net Sales by Region**

<u>United States</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $291 | $374 | $(83) | (22.2%) | $886 | $1089 | $(203) | (18.6%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unfavorable foreign exchange impact |  |  |  | —% |  |  |  | —% |
| **Constant currency** |  |  |  | (22.2%) |  |  |  | (18.6%) |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three months ended September 30, 2025 was primarily due to lower volumes of Byte products following the suspension of sales in 2024, and lower volumes of CAD/CAM and imaging equipment. The decrease was also due to unfavorable pricing for restorative products and lower volumes of preventive and restorative consumable products as a result of distributor orders placed in the third quarter of 2024 in advance of our implementation of a new ERP system in the fourth quarter of 2024. Sales for CAD/CAM products were negatively impacted by a lower quarterly increase in distributor inventory levels of approximately $20 million in the three months ended September 30, 2025, compared to approximately $36 million in the three months ended September 30, 2024. Sales for imaging products were negatively impacted by a decrease in distributor inventory levels of approximately $1 million in the three months ended September 30, 2025, compared to an increase of approximately $10 million in the three months ended September 30, 2024. Sales for consumables products were negatively impacted by a decrease in distributor inventory levels of approximately $4 million in the three months ended September 30, 2025, compared to an increase of approximately $20 million in the three months ended September 30, 2024.

------

The net sales decrease on a constant currency basis for the nine months ended September 30, 2025 was primarily driven by the suspension of Byte sales. The decrease was also due to lower volumes of CAD/CAM and imaging equipment, implants and prosthetics products, and preventive and restorative products, partially offset by higher volumes of treatment centers. Sales for CAD/CAM products were negatively impacted by a lower quarterly increase in distributor inventory levels of approximately $4 million in the nine months ended September 30, 2025 compared to an increase of approximately $32 million in the nine months ended September 30, 2024. Volumes for imaging products were not significantly impacted by changes in the levels of distributor inventory during the nine months ended September 30, 2025. Sales for consumables products were negatively impacted by a decrease in distributor inventory levels of approximately $4 million in the nine months ended September 30, 2025, compared to an increase of approximately $21 million in the nine months ended September 30, 2024. Distributor inventory levels for both CAD/CAM and imaging products at September 30, 2025 remain below historical averages.

<u>Europe</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $382 | $347 | $35 | 9.9% | $1148 | $1110 | $38 | 3.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable foreign exchange impact |  |  |  | 7.3% |  |  |  | 2.4% |
| **Constant currency** |  |  |  | 2.6% |  |  |  | 1.1% |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales increase on a constant currency basis for the three and nine months ended September 30, 2025 was primarily driven by higher volumes of treatment centers, imaging equipment, and Wellspect Healthcare products, partially offset by lower volumes of CAD/CAM equipment. For the nine months ended September 30, 2025, these increases were partially offset by lower volumes of implants and prosthetics.

<u>Rest of World</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| **Net sales** | $231 | $230 | $1 | 0.3% | $685 | $689 | $(4) | (0.6%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Favorable foreign exchange impact |  |  |  | 1.2% |  |  |  | (1.5%) |
| **Constant currency** |  |  |  | (0.9%) |  |  |  | 0.9% |

---

Percentages are based on actual values and may not reconcile due to rounding.

The net sales decrease on a constant currency basis for the three months ended September 30, 2025 was primarily due to lower volumes of CAD/CAM equipment and implants products, partially offset by higher volumes of products within the Essential Dental Solutions and Wellspect Healthcare segments.

The net sales increase on a constant currency basis for the nine months ended September 30, 2025 was primarily driven by higher volumes of products within the Essential Dental Solutions and Wellspect Healthcare segments, partially offset by lower volumes of CAD/CAM equipment and lower volumes and unfavorable pricing on implants products.

------

**Gross Profit**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| Gross profit | $441 | $495 | $(54) | (11.0%) | $1397 | $1512 | $(115) | (7.6%) |
| Gross profit as a percentage of net sales | 48.8% | 52.1% | (330) bps |  | 51.4% | 52.4% | (100) bps |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit as a percentage of net sales for the three months ended September 30, 2025 decreased primarily due to unfavorable product mix and pricing for CAD/CAM and restorative consumable products, as well as tariff costs, partially offset by a benefit from foreign currency.

Gross profit as a percentage of net sales for the nine months ended September 30, 2025 decreased primarily due to unfavorable product mix and pricing for CAD/CAM, implants, and restorative consumable products, as well as tariff costs. These decreases were partially offset by lower manufacturing costs and a benefit from foreign currency translation.

**Operating Expenses**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| Selling, general, and administrative expenses ("SG&A") | $355 | $390 | $(35) | (8.8%) | $1055 | $1204 | $(149) | (12.3%) |
| Research and development expenses ("R&D") | 37 | 40 | (3) | (9.2%) | 110 | 123 | (13) | (10.9%) |
| Goodwill and intangible asset impairments | 262 | 504 | (242) | NM | 497 | 510 | (13) | NM |
| Restructuring and other costs | 5 | 23 | (18) | NM | 18 | 45 | (27) | NM |
| SG&A as a percentage of net sales | 39.4% | 41.0% | (160) bps |  | 38.8% | 41.7% | (290) bps |  |
| R&D as a percentage of net sales | 4.1% | 4.2% | (10) bps |  | 4.0% | 4.3% | (30) bps |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

------

<u>SG&A Expenses</u>

The decrease in SG&A expenses for the three and nine months ended September 30, 2025 was primarily driven by lower marketing expenses, particularly due to the absence of marketing for Byte products, and lower headcount costs as a result of restructuring and cost-saving initiatives.

<u>R&D Expenses</u>

For the three and nine months ended September 30, 2025, R&D expenses decreased as the Company continues to prioritize a disciplined approach with ongoing investments in digital workflow solutions, product development initiatives, and software development, including clinical application suite and cloud deployment. The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

<u>Goodwill and Intangible Asset Impairments</u>

For the three months ended September 30, 2025, the Company recorded pre-tax goodwill impairment charges of $253 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment and indefinite-lived intangible asset impairment charges of $4 million and $5 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively.

For the nine months ended September 30, 2025, the Company recorded pre-tax goodwill impairment charges of $409 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The Company also recorded intangible asset impairment charges of $68 million within the Connected Technology Solutions unit and $20 million within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

<u>Restructuring and Other Costs</u>

The Company recorded restructuring and other costs of $5 million and $18 million for the three and nine months ended September 30, 2025, respectively, and $23 million and $45 million for the three and nine months ended September 30, 2024, respectively. The expenses in 2025 primarily consist of costs in connection with various restructuring initiatives. The expenses in 2024 consisted primarily of severance costs in conjunction with the restructuring plans announced in February 2023 and July 2024. For further details refer to *Material Trends in Capital Resources* below, and Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

**Segment Adjusted Operating Income**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages)<sup>(a)</sup> | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| Connected Technology Solutions | $10 | $16 | $(6) | (42.6%) | $29 | $21 | $8 | 32.4% |
| Essential Dental Solutions | 116 | 132 | (16) | (11.5%) | 403 | 372 | $31 | 8.4% |
| Orthodontic and Implant Solutions | 22 | 24 | (2) | (3.8%) | 104 | 108 | $(4) | (3.2%) |
| Wellspect Healthcare | 28 | 26 | 2 | 13.3% | 78 | 73 | $5 | 9.6% |

---

Percentages are based on actual values and may not reconcile due to rounding.

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

------

<u>Connected Technology Solutions</u>

The decrease in segment adjusted operating income for the three months ended September 30, 2025 is due to lower net sales on a constant currency basis and tariff costs, partially offset by favorable manufacturing variances. The increase in segment adjusted operating income for the nine months ended September 30, 2025 is due to lower headcount-related costs and professional service costs, partially offset by lower net sales on a constant currency basis.

<u>Essential Dental Solutions</u>

The decrease in segment adjusted operating income for the three months ended September 30, 2025 is due to lower net sales on a constant currency basis, unfavorable pricing, and tariff costs, partially offset by lower headcount costs. The increase in segment adjusted operating income for the nine months ended September 30, 2025 is due to lower headcount costs and professional service costs, partially offset by lower net sales on a constant currency basis.

<u>Orthodontic and Implant Solutions</u>

The decrease in segment adjusted operating income for the three and nine months ended September 30, 2025 is due to the lower volumes of direct-to-consumer aligners and implants and prosthetics products and tariff costs, partially offset by lower headcount costs and professional service costs. During the nine months ended September 30, 2025, results also included favorable adjustments for estimated customer refunds and bad debt reserves for the Byte aligner business.

<u>Wellspect Healthcare</u>

The increase in segment adjusted operating income for the three and nine months ended September 30, 2025 is due to higher net sales on a constant currency basis as a result of new product launches.

**Other Income and Expense**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change |
| &nbsp;&nbsp;Interest expense, net | $23 | $18 | $5 | 34.4% | $66 | $53 | $13 | 25.9% |
| &nbsp;&nbsp;Other income | (11) | (2) | (9) | NM | (10) | (10) |  | NM |
| Net interest and other expense (income) | $12 | $16 | $(4) |  | $56 | $43 | $13 |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

<u>Interest expense, net</u>

Interest expense, net for the three and nine months ended September 30, 2025 increased compared to the three and nine months ended September 30, 2024 primarily due to a higher average carrying balance of total borrowings.

<u>Other income</u>

Other income for the three and nine months ended September 30, 2025 compared to the three and nine months ended September 30, 2024 is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | 2025 | 2024 | $ Change |
| &nbsp;&nbsp;Foreign exchange gains <sup>(a)</sup> | $(13) | $(3) | $(10) | $(13) | $(17) | $4 |
| &nbsp;&nbsp;Defined benefit pension plan expenses | 3 | 1 | 2 | 5 | 6 | (1) |
| &nbsp;&nbsp;Other non-operating (income) expense | (1) |  | (1) | (2) | 1 | (3) |
| Other income | $(11) | $(2) | $(9) | $(10) | $(10) | $— |

---

------

(a) Foreign exchange gains include a benefit from our net investment hedges totaling $15 million, offset by revaluation of short-term intercompany receivables and payables of $2 million.

**Income Taxes and Net Income**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended September 30, | Three Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions, except percentages) | 2025 | 2024 | $ Change | 2025 | 2024 | $ Change |
| Provision for income taxes | $198 | $17 | $181 | $114 | $69 | $45 |
| Effective income tax rate | (86.5%) | (3.3%) |  | (33.6%) | (16.7%) |  |
| Net loss attributable to Dentsply Sirona | $(427) | $(494) | $67 | $(452) | $(480) | $28 |
| Diluted loss per common share | $(2.14) | $(2.46) |  | $(2.27) | $(2.35) |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

<u>Provision for income taxes</u>

The effective tax rates for the three months ended September 30, 2025 and 2024 were (86.5%) and (3.3%), respectively. For the nine months ended September 30, 2025 and 2024, the rates were (33.6%) and (16.7%), respectively. The decrease in effective tax rate is primarily driven by goodwill and intangible asset impairments, the majority of which are not deductible for tax purposes.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law in the United States. The OBBBA includes significant provisions, including tax cut extensions and modifications to the international tax framework. The Company evaluated the impact of the OBBBA and concluded that the effect is not material to the financial results.

------

**CRITICAL ACCOUNTING ESTIMATES**

**Goodwill and Indefinite-Lived Intangible Assets**

Goodwill represents the excess cost over the fair value of the identifiable net assets of business acquired and is allocated among the Company's reporting units. Indefinite-lived intangible assets consist of trade names, trademarks, and in-process R&D. Neither goodwill nor indefinite-lived intangible assets are amortized; instead, they are tested for impairment annually at April 1 or more frequently if events or circumstances indicate that the carrying value may be impaired, or if a decision is made to sell, discontinue, or divest a business. Judgment is involved in determining if an indicator of impairment has occurred during the year. Such indicators may include a decline in expected cash flows, unanticipated competition, increased interest rates, or slower growth rates, among others.

<u>Impairment Test Results</u>

The Company assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2025. As a result of the Company's April 1 impairment test, it was determined that the fair values of its Implant & Prosthetic Solutions reporting unit and certain indefinite-lived intangible assets, including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment were below their carrying values.

The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was primarily driven by the impact of tariffs and lower projected volumes, due partly to competitive pressures, particularly in the United States and European markets. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term. As a result of this test, the Company recorded a pre-tax goodwill impairment charge as of June 30, 2025 of $156 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment.

As a result of the annual test of indefinite-lived intangible assets, the Company identified impairments of certain trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The decline in fair value of these assets was driven by the impact of tariffs, which reduced the royalty rates used to value these assets, and lower volumes for the Company's equipment and implant products due partly to competitive pressure, which contributed to reduced forecasted revenues. As a result of this test, the Company recorded pre-tax charges of $79 million to intangible assets as of June 30, 2025, consisting of $64 million within the Connected Technology Solutions segment and $15 million within the Implant & Prosthetic Solutions reporting unit, which were recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

For the three months ended September 30, 2025, the Company considered additional qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in indicators of additional impairment of goodwill or indefinite-lived intangible assets. Due to the lower-than-expected results for Implant & Prosthetic Solutions, it was determined that the fair value of this reporting unit had declined below its carrying value. The updated fair value was computed in a manner consistent with the annual test described above, with the decline primarily driven by lower-than-expected volumes, particularly in the United States, and the impact of tariffs. As a result of the updated impairment testing, as of September 30, 2025 the Company recorded a pre-tax goodwill impairment charge of $253 million for the Implant & Prosthetic Solutions reporting unit. Additionally, review of the indefinite-lived intangible assets previously impaired as of June 30, 2025, using a consistent methodology as that which was used for the annual test, indicated a further decline in fair value as of September 30, 2025 due to lower volumes for the Company's equipment and implant products. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $4 million and $5 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2025.

For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

------

**LIQUIDITY AND CAPITAL RESOURCES**

---

| | | | |
|:---|:---|:---|:---|
| | Nine Months Ended September 30, | Nine Months Ended September 30, | Nine Months Ended September 30, |
| (in millions) | 2025 | 2024 | $ Change |
| **Cash provided by (used in):** |  |  |  |
| &nbsp;&nbsp;Operating activities | $134 | $374 | $(240) |
| &nbsp;&nbsp;Investing activities | (87) | (140) | 53 |
| &nbsp;&nbsp;Financing activities | 19 | (264) | 283 |
| &nbsp;&nbsp;Effect of exchange rate changes on cash and cash equivalents | 25 | (8) | 33 |
| Net increase (decrease) in cash and cash equivalents | $91 | $(38) | $129 |

---

Cash provided by operating activities decreased compared to the nine months ended September 30, 2024, primarily as a result of lower net sales and changes in working capital, including higher accounts receivable due largely to timing of sales and customer remittances and higher build of inventory during the current period. At September 30, 2025, the number of days for sales outstanding in accounts receivable increased by 9 days to 64 days as compared to 55 days at December 31, 2024, and the number of days of sales in inventory increased by 21 days to 145 days at September 30, 2025 as compared to 124 days at December 31, 2024.

Cash used in investing activities decreased compared to the nine months ended September 30, 2024, due to lower capital expenditures of $39 million, an increase in cash received on derivative contracts of $10 million due to the series of USD to CHF cross currency basis swaps the Company entered into on July 1, 2025, and a decrease in cash paid on the settlement of derivatives of $3 million due to the interest rate swap closure in the prior year. The Company estimates capital expenditures to be in the range of approximately $130 million to $140 million for the full year 2025 and expects these investments to include expenses for the ongoing implementation of a new global ERP system, equipment upgrades, and capacity expansion to support product innovation and consolidate operations for enhanced efficiencies.

On March 19, 2025, the Company entered into a 364-day term loan of $435 million with a maturity date of March 18, 2026 (the "Bridge Loan Facility"). The proceeds were $432 million, net of issuance fees totaling $3 million. The net proceeds from the Bridge Loan Facility were used to repay indebtedness under the Company's commercial paper facility and pre-fund repayment of certain other short-term indebtedness. Subsequently, on June 12, 2025, the Company issued $550 million aggregate principal amount of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 (the "Notes") through a public offering. The proceeds from the sale of the Notes were $545 million, after deduction of underwriters' fees. On June 12, 2025, the Company used a portion of these proceeds to repay in full the outstanding principal and accrued interest due under the Bridge Loan Facility, which was then terminated as a result of the repayment. The Company intends to use the remaining proceeds from the sale of the Notes for general corporate purposes.

Cash provided by financing activities increased compared to the nine months ended September 30, 2024 primarily as a result of the Company entering into the Notes as described above. The increase in cash provided by financing activities was mostly offset by repayments on the Bridge Loan Facility and commercial paper facility. The Company also had lower payments for repurchase of treasury stock of $250 million compared to the nine months ended September 30, 2024.

On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. At September 30, 2025, the Company had $1.19 billion of authorization remaining available for share repurchases. Additional share repurchases, if any, may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. At September 30, 2025, the Company held 65.0 million shares of treasury stock.

------

The Company's ratio of total net debt to total capitalization was as follows:

---

| | | |
|:---|:---|:---|
| (in millions, except percentages) | September 30, 2025 | December 31, 2024 |
| &nbsp;&nbsp;Notes payable and current portion of debt | $378 | $549 |
| &nbsp;&nbsp;Long-term debt | 2017 | 1586 |
| &nbsp;&nbsp;Less: Cash and cash equivalents | 363 | 272 |
| Net debt | $2032 | $1863 |
| &nbsp;&nbsp;Total equity | 1478 | 1943 |
| Total capitalization | $3510 | $3806 |
| **Total net debt to total capitalization ratio** | **57.9%** | **48.9%** |

---

At September 30, 2025, the Company had $736 million of borrowings available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company's borrowing capacity includes a $700 million multi-currency credit facility which expires in May 2028. The Company also has access to an aggregate $700 million under a U.S. dollar commercial paper facility. The $700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is $700 million. The Company had no outstanding borrowings under the commercial paper facility at September 30, 2025, resulting in $700 million remaining available under the revolving credit and commercial paper facilities. The Company also has access to $42 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At September 30, 2025, the Company had $5 million outstanding under short-term borrowing arrangements.

The Company's revolving credit facility and senior notes contain certain covenants relating to the Company's operations and financial condition. The most restrictive of these covenants after the amendments noted below include the following: (1) a ratio of senior debt to capitalization not to exceed 0.6, and (2) a ratio of operating income excluding depreciation and amortization to interest expense of not less than 3.0 times, in each case, as such terms are defined in the relevant agreement. Any breach of any such covenants would result in a default under the existing debt agreements that would permit the lenders to declare all borrowings under such debt agreements to be immediately due and payable and, through cross default provisions, would entitle the Company's other lenders to accelerate their loans. At September 30, 2025, the Company was in compliance with these covenants.

On June 3, 2025, the Company entered into agreements with the applicable noteholders to amend certain provisions of its private placement notes and also obtained the consent of the requisite lenders under its revolving credit facility to amend certain provisions of that credit agreement. Under the amended terms, the Company and the relevant counterparties agreed to, among other things: (i) establish the financial covenant noted above requiring that the ratio of senior debt to capitalization shall not exceed 0.6, (ii) increase the maximum allowable consolidated leverage ratio to 0.65, (iii) adjust the German subsidiary debt to be treated as permitted debt under a newly designated standalone basket, and (iv) implement provisions governing interest rate adjustments in the event that the Company's credit rating is downgraded below investment grade.

The Company expects on an ongoing basis to be able to finance operating cash requirements, capital expenditures, and debt service from the current cash, cash equivalents, cash flows from operations and amounts available under its existing borrowing facilities. The Company's credit facilities are further discussed in Note 12, Financing Arrangements, to the Unaudited Consolidated Financial Statements of this Form 10-Q.

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operating activities and future foreign investments. The Company has the ability to repatriate cash to the United States, which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At September 30, 2025, management believed that sufficient liquidity was available in the United States and expects this to continue for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations. Repatriation activities both performed and contemplated to date have not resulted in, and are not expected to result in, any significant incremental tax liability to the Company.

------

The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near term based on strategic capital management. The Company believes there is sufficient liquidity available for the next twelve months.

**Restructuring Plans**

On July 29, 2024, the Board of Directors of the Company approved a plan to restructure the Company's business to improve operational performance and drive stockholder value creation (the "2024 Plan"). In connection with the 2024 Plan, the Company anticipates a net reduction in the Company's global workforce of approximately 2% to 4%. The Company anticipates that the 2024 Plan will be substantially completed by the end of 2025 and result in $80 million to $100 million in annual cost savings. The proposed changes are subject to co-determination processes with employee representative groups in countries where required.

As of September 30, 2025, in connection with the 2024 Plan, the Company has incurred $30 million in restructuring charges from inception, primarily related to employee transition, severance payments and employee benefits, which are expected to be paid by the end of 2025. Actions taken under the 2024 Plan will seek to streamline the Company's operations and global footprint, as well as improve alignment of the Company's cost structure with its strategic growth objectives. Remaining restructuring charges attributable to the 2024 Plan are not expected to be material.

On February 14, 2023, the Board of Directors of the Company approved a plan to restructure the Company's business through a new operating model with five global business units, optimize central functions and overall management infrastructure, and implement other efforts aimed at cost savings (the "2023 Plan"). The Company estimated a reduction in its global workforce of approximately 8% to 10% and annual cost savings of approximately $200 million pursuant to the 2023 Plan. The target for cost savings has been substantially met, with the benefits mostly offset in the short term by additional investments in sales personnel, the Company's new global ERP system, and other transformation initiatives. During the course of 2023 and 2024, the Company incurred $86 million in restructuring charges in conjunction with the 2023 Plan, primarily related to employee transition, severance payments, employee benefits, and facility closure costs, and $20 million in other non-recurring costs related to restructuring activities which mostly consist of consulting, legal and other professional service fees. Remaining restructuring charges attributable to the 2023 Plan are not expected to be material.

For further details refer to Note 8, Restructuring and Other Costs, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

**NEW ACCOUNTING PRONOUNCEMENTS**

Refer to Part I, Item 1, Note 1, Business and Basis of Presentation, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.

------

**Item 3 – Quantitative and Qualitative Disclosures about Market Risk**

There have been no material changes from the information provided in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in our 2024 Form 10-K.

**Item 4 – Controls and Procedures**

<u>Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</u>

The Company's management, with the participation of the Company's Chief Executive Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.

<u>Changes in Internal Control Over Financial Reporting</u>

The Company has committed to a multi-year project to implement a new ERP system using a global platform. The implementation is underway and is expected to continue to occur in phases over the next several years. In connection with the ERP implementation, we are updating and will continue to update our internal control over financial reporting, as necessary, to accommodate modifications to our business processes and accounting procedures.

Except with respect to the continued implementations of the new ERP system, there have been no changes in our internal control over financial reporting during the three and nine months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We will continue to evaluate any further changes that could materially affect, or are reasonably likely to materially affect, our internal control over financial reporting over the course of the implementation of the new ERP system and other related systems.

------

**PART II – OTHER INFORMATION**

**Item 1 – Legal Proceedings**

Refer to Part I, Item 1, Note 14 Commitments and Contingencies, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

**Item 1A – Risk Factors**

Except as set forth below, there have been no material changes to the risk factors as disclosed in Part I, Item 1A, "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024.

**We have recognized substantial goodwill and indefinite-lived intangible asset impairment charges, most recently in the quarter ended September 30, 2025, and may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future.**

We have acquired other companies and intangible assets and may not realize all the economic benefit from those acquisitions, which could cause an impairment of goodwill or intangibles. We review amortizable intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. We test goodwill and indefinite-lived intangibles for impairment at least annually. The valuation models used to determine the fair value of goodwill or indefinite-lived intangible assets are dependent upon various assumptions and reflect management's best estimates.

The Company assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2025. As a result of the Company's April 1 impairment test, it was determined that the fair values of its Implant & Prosthetic Solutions reporting unit and certain indefinite-lived intangible assets including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment were below their carrying values.

The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was primarily driven by the impact of tariffs and lower projected volumes, particularly in the United States and European markets. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term. As a result of this test, the Company recorded a pre-tax goodwill impairment charge as of June 30, 2025 of $156 million for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment.

As a result of the annual test of indefinite-lived intangible assets, the Company identified impairments of certain trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment. The decline in fair value of these assets was driven by the impact of tariffs, which reduced the royalty rates used to value these assets, and lower volumes for the Company's equipment and implant products which contributed to reduced forecasted revenues. As a result of this test, the Company recorded pre-tax charges of $79 million to intangible assets as of June 30, 2025, consisting of $64 million within the Connected Technology Solutions segment and $15 million within the Implant & Prosthetic Solutions reporting unit, which were recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

------

For the three months ended September 30, 2025, the Company considered additional qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in indicators of additional impairment of goodwill or indefinite-lived intangible assets. Due to the lower-than-expected results for Implant & Prosthetic Solutions, it was determined that the fair value of this reporting unit had declined below its carrying value. The updated fair value was computed in a manner consistent with the annual test described above, with the decline primarily driven by lower-than-expected volumes, particularly in the United States, and the impact of tariffs. As a result of the updated impairment testing, as of September 30, 2025 the Company recorded a pre-tax goodwill impairment charge of $253 million for the Implant & Prosthetic Solutions reporting unit. Additionally, review of the indefinite-lived intangible assets previously impaired as of June 30, 2025, using a consistent methodology as that which was used for the annual test, indicated a further decline in fair value as of September 30, 2025 due to lower volumes for the Company's equipment and implant products. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $4 million and $5 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2025.

Following these impairments, the fair values of the Implant & Prosthetic Solutions reporting unit and the abovementioned indefinite-lived intangible assets continued to approximate their carrying values as of September 30, 2025. Any further decline in key assumptions, such as an increase in the discount rate by 50 basis points or further reduction in projected revenues or margins, would likely lead to additional material impairments of the Implant & Prosthetic Solutions reporting unit, the above-mentioned intangible assets, or both. Additionally, the fair value of other assets within the Connected Technology Solutions segment, including fixed assets and definite-lived intangible assets, may be at risk of material impairment if forecasted revenues or margins for this business decline further, or if the Company is not able to adequately mitigate the impact of tariff costs in future years. Remaining goodwill associated with the Implant & Prosthetic Solutions reporting unit was $123 million as of September 30, 2025, which represents all remaining goodwill within the Orthodontic and Implant Solutions segment. The remaining carrying values of the indefinite-lived intangible assets within the Connected Technology Solutions and Orthodontic and Implant Solutions segments approximate fair value and were $105 million and $90 million, respectively, as of September 30, 2025.

The goodwill and indefinite-lived intangible asset impairment analyses are sensitive to changes in key assumptions used, such as discount rates, revenue growth rates, perpetual revenue growth rates, operating margin percentages, and net working capital assumptions of the business as well as current market conditions affecting the dental and medical device industries in both the United States and globally. Given the uncertainty in the marketplace and other factors affecting management's assumptions underlying our discounted cash flow model, the assumptions and projections used in the analyses may not be realized and our current estimates could vary significantly in the future, which may result in one or more additional goodwill or indefinite-lived intangible asset impairment charges in the future.

For further information on the annual impairment test of goodwill and intangible assets, see Note 13, Goodwill and Intangible Assets, in the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

There is a risk of future impairment charges if there is a decline in the fair value of the reporting units or indefinite-lived intangible assets as a result of, among other things, actual financial results that are lower than forecasts, an adverse change in valuation assumptions, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets. There can be no assurance that the Company's future asset impairment testing will not result in a material charge to earnings. Additionally, any such material impairment charges in future periods could result in violations of the Company's current debt covenants. The Company is committed to maintaining compliance with its debt covenants in all material respects, including proactively seeking temporary or permanent amendments or waivers to avoid breaching such covenants.

At September 30, 2025, following the above-mentioned impairments, the Company has $291 million of indefinite-lived intangible assets and $1.3 billion of goodwill recorded on its balance sheet. Additionally, the fair value of other assets within the Connected Technology Solutions segment, including fixed assets and definite-lived intangible assets, may be at risk of material impairment if forecasted revenues or margins for this business decline further, or if the Company is not able to adequately mitigate the impact of tariff costs in future years. Total net assets for this segment are $765 million as of September 30, 2025.

------

**Item 2 – Unregistered Sales of Securities and Use of Proceeds**

During the three months ended September 30, 2025, the Company had no repurchases of common shares under the stock repurchase program.

On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. At September 30, 2025, the Company had authorization to repurchase $1.19 billion in shares of common stock remaining under the share repurchase program.

**Item 5 - Other Information**

Rule 10b5-1 Trading Plans

During the three months ended September 30, 2025, none of the Company's directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.

------

**Item 6 – Exhibits**

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | <u>Description</u> |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/818479/000081847925000137/ex101employmentagreement.htm)</u> | Employment Agreement by and between DENTSPLY SIRONA Inc. and Daniel Scavilla, dated July 18, 2025\* (1) |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/818479/000081847925000137/ex102separationandreleas.htm)</u> | Separation and Release of Claims Agreement by and between DENTSPLY SIRONA Inc. and Simon D. Campion, dated July 20, 2025\* (1) |
| <u>[10.3](ex103formofdirectoroptio.htm)</u> | Form of Option Award Agreement (Director) under the Dentsply Sirona Inc. 2024 Omnibus Incentive Plan\* (Filed herewith) |
| <u>[10.4](https://www.sec.gov/Archives/edgar/data/818479/000081847925000182/ex101separationagreement.htm)</u> | Transition, Separation and Release of Claims Agreement by and between DENTSPLY SIRONA Inc. and Richard C. Rosenzweig, dated October 2, 2025\* (2) |
| <u>[31](exhibit31q32025.htm)</u> | Section 302 Certification Statement of the Chief Executive Officer (Filed herewith) |
| <u>[32](exhibit32q32025.htm)</u> | Section 906 Certification Statement (Furnished herewith) |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Extension Labels Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
| \*Management contract or compensatory plan. | \*Management contract or compensatory plan. |
| (1) Incorporated by reference to exhibit included in the Company's Form 8-K dated July 18, 2025, File no. 0-16211. | (1) Incorporated by reference to exhibit included in the Company's Form 8-K dated July 18, 2025, File no. 0-16211. |
| (2) Incorporated by reference to exhibit included in the Company's Form 8-K dated October 3, 2025, File no. 0-16211. | (2) Incorporated by reference to exhibit included in the Company's Form 8-K dated October 3, 2025, File no. 0-16211. |

---

------

<u>Signatures</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DENTSPLY SIRONA Inc.**

---

| | | |
|:---|:---|:---|
| */s/* | *Daniel T. Scavilla* | November 6, 2025 |
| | Daniel T. Scavilla | Date |
| | President and Chief Executive Officer | |

---

## Exhibit 10.3

![](ex103formofdirectoroptio001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OPTION GRANT NOTICE UNDER THE DENTSPLY SIRONA INC. 2024 OMNIBUS INCENTIVE PLAN as amended and restated OPTION GRANT NOTICE (for Directors) Notice is hereby given of the following option grant (the "Option") to purchase Common Stock, $0.01 par value per share, of DENTSPLY SIRONA Inc. ("Common Shares" or "Shares") pursuant to the following terms and conditions: • Optionee: Participant Name • Grant Date: Grant Date • Exercise Price per Share: Grant Price • Number of Option Shares: Quantity Granted • Term/Expiration Date of Option: Expiration Date • Type of Option: Non-Qualified Stock Option • Vesting Schedule: The Option shall vest and become exercisable in accordance with the vesting schedule specified herein, subject to your continuous service with the Company through such date (except as may otherwise be provided in Exhibit A attached hereto): Vesting Schedule (Dates & Quantities) • Other Provisions: The Option is granted subject to, and in accordance with, the terms of the Option Agreement (the "Option Agreement") attached hereto as Exhibit A and the DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan, as amended and restated from time to time (the "Plan"). Notwithstanding anything to the contrary set forth herein, except as may otherwise be provided in Exhibit A attached hereto, if your service with the Company terminates for any reason prior to the vesting of the Option, you shall forfeit all rights with respect to this Option (and the underlying Common Shares).

------

![](ex103formofdirectoroptio002.jpg)

This Option is granted under, and governed by, the terms and conditions of this Grant Notice, the Plan, and the Option Agreement. DENTSPLY SIRONA INC. Attachments: Exhibit A—Option Agreement (for Directors)

------

![](ex103formofdirectoroptio003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;EXHIBIT A OPTION AGREEMENT DENTSPLY SIRONA Inc., a Delaware corporation (the "Company"), has granted you (the "Optionee") an option to purchase common shares of the Company, $0.01 par value per share ("Common Shares"), pursuant to the terms and conditions set forth in your Option Grant Notice (the "Grant Notice") and this Option Agreement (this "Option Agreement"). The Option (as defined below) is granted pursuant to the DENTSPLY SIRONA Inc. 2024 Omnibus Incentive Plan, as amended and restated from time to time (the "Plan"), pursuant to which options, and other awards, may be granted to Eligible Recipients under the Plan. Except as otherwise specifically set forth herein, all capitalized terms utilized herein shall have the respective meanings ascribed to them in the Plan. The details of your Option are as follows: 1. Grant of Option. Pursuant to an action of the Board and/or the Committee, the Company hereby grants to Optionee an option to purchase Common Shares (the "Option"), subject to the terms and conditions described herein. The number of Common Shares subject to your Option and the Exercise Price per Share are set forth in the Grant Notice. 2. Term, Vesting and Forfeiture. (a) Term. This Option may be exercised only within the Term set forth in the Grant Notice, and may be exercised during such Term only in accordance with the Plan and the terms of this Option Agreement and Grant Notice. (b) Time Vesting. The Option shall vest in one or more installments in accordance with the Vesting Schedule set forth on the Grant Notice, with the vesting of each installment subject to Optionee's continuous service with the Company through the applicable vesting date, subject to such additional terms and conditions set forth on the Grant Notice and the terms hereof. (c) Accelerated Vesting. Any Option, or portion thereof, which has not yet vested under subparagraph (b) above shall vest or be forfeited in accordance with the provisions of the Plan and the terms of this Option Agreement. (d) Forfeiture of Option. Except as otherwise provided in the Grant Notice, this Option Agreement, or the Plan, if Optionee's service with the Company terminates for any reason, Optionee shall

------

![](ex103formofdirectoroptio004.jpg)

forfeit all rights with respect to any portion of the Option that has not yet vested as of the effective date of the termination of service without payment therefor. Notwithstanding the foregoing: (i) If Optionee's service with the Company is terminated by the Company for Cause (including on account of Optionee being removed from the Board for Cause), Optionee (or Optionee's beneficiary) shall not be entitled to exercise all or any part of the Option, whether or not then vested; and (ii) if Optionee's service with the Company is terminated for any reason other than Cause, then Optionee (or Optionee's beneficiary) shall be entitled to exercise all or any part of any vested Option for a period of ninety (90) days after the termination of Optionee's service. 3. Exercise of Option. (a) Right to Exercise. This Option is exercisable during its Term in accordance with the Vesting Schedule set forth in the Grant Notice and the applicable provisions of the Plan and this Option Agreement. Only vested portions of the Option may be exercised. (b) Method of Exercise. This Option is exercisable pursuant to the procedures for exercise provided from time to time by the Administrator and/or by a third-party vendor selected by the Administrator, and in accordance with the terms of the Plan. The Option exercise shall require payment of the aggregate exercise price as to all exercised shares. The method of payment of the aggregate exercise price shall be in a form approved by the Administrator in accordance with Section 7 of the Plan. This Option shall be deemed to be exercised upon receipt and approval by the Administrator (or the appropriate third party) of all required exercise notices, together with full payment of the exercise price and such additional documents as the Administrator (or the third-party vendor) may then require. 4. Incorporation of the Plan by Reference; Conflicting Terms. The Option is granted under, and expressly subject to, the terms and provisions of the Plan, which terms and provisions are incorporated herein by reference. Optionee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof. In the event of any conflict between the terms of the Plan and the terms of this Option Agreement, the terms and provisions of the Plan shall govern. 5. Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Optionee.

------

![](ex103formofdirectoroptio005.jpg)

6. Stockholder Rights. Optionee shall not have any stockholder rights with respect to the Common Shares granted pursuant to this Option until Optionee shall have exercised the Option in accordance with Section 3 hereof. 7. Committee Discretion. This Option has been granted pursuant to a determination made by the Board and/or Committee. Notwithstanding anything to the contrary herein, and subject to the limitations of the Plan, the Administrator shall have plenary authority to: (a) interpret any provision of this Option Agreement or the Option; (b) make any determinations necessary or advisable for the administration of this Option Agreement or the Option; (c) make adjustments as it deems appropriate to the aggregate number and type of securities available under this Option Agreement to appropriately adjust for, and give effect to, any Change in Capitalization or otherwise as provided under the Plan; and (d) otherwise modify or amend any provision hereof, or otherwise with respect to the Option, in any manner that does not materially and adversely affect any right granted to Optionee by the express terms hereof, unless required as a matter of law, subject to the limitations stated in the Plan. 8. Tax Withholding. The Company shall withhold from Optionee's compensation any required taxes, including social security and Medicare taxes, and federal, state and local income tax, with respect to the income arising from the exercise or payment in respect of any portion of the Option under this Option Agreement (or such other amount that will not cause adverse accounting consequences for the Company and is permitted under applicable withholding rules promulgated by the Internal Revenue Service or other applicable governmental entity), but only if such withholding is required. Optionee shall be responsible for all tax consequences with respect to the Option and Optionee's participation in the Plan. 9. Clawback Policy. To the extent this Award is subject to recovery under any law, government regulation, stock exchange listing requirement or Company agreement or policy, this Award will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any agreement or policy adopted by the Company pursuant to any such law, government regulation, stock exchange listing requirement or otherwise). 10. Electronic Delivery. The Company may choose to deliver certain statutory or regulatory materials relating to the Plan in electronic form, including without limitation securities law disclosure materials. Without limiting the foregoing, by accepting this Option, Optionee hereby agrees that the Company may deliver the Plan prospectus and the Company's annual report to Optionee in an electronic format. If at any time Optionee would prefer to receive paper copies of any document delivered in electronic form, the Company will provide such paper copies upon written request to the Investor Relations department of the Company.

------

![](ex103formofdirectoroptio006.jpg)

11. No Right to Continued Service. Nothing in this Option Agreement shall be deemed to create any limitation or restriction on such rights as the Company otherwise would have to terminate the service of Optionee at any time for any reason. 12. Entire Agreement; Severability. This Option Agreement, the Plan and the Grant Notice contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings and negotiations between the parties. If any of the provisions of this Option Agreement are determined, for any reason, to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Option Agreement. 13. Governing Law. To the extent federal law does not otherwise control, this Option Agreement shall be governed by the laws of Delaware, without giving effect to principles of conflicts of laws. 14. Insider Trading Restrictions/Market Abuse Laws. Optionee may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, which may affect Optionee's ability to, directly or indirectly, accept, acquire, sell, or attempt to sell or otherwise dispose of Common Shares or rights to Common Shares during such times when Optionee is considered to have "inside information" regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or Optionee's country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders placed by Optionee before possessing inside information. Furthermore, Optionee understands that Optionee may be prohibited from (a) disclosing the inside information to any third party, including fellow Non-Employee Directors (other than on a "need to know" basis) and (b) "tipping" third parties or causing them to otherwise buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Optionee acknowledges that Optionee is responsible for ensuring compliance with any applicable restrictions and should consult Optionee's personal legal advisor on these matters.

------

## Ex-31

Exhibit 31

<u>Section 302 Certifications Statement</u>

I, Daniel T. Scavilla, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Form 10-Q of DENTSPLY SIRONA Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2025

---

| | |
|:---|:---|
| */s/* | *Daniel T. Scavilla* |
| | Daniel T. Scavilla |
| | President and |
| | Chief Executive Officer |

---

## Ex-32

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DENTSPLY SIRONA Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Daniel T. Scavilla, President and Chief Executive Officer of the Company, and Matthew E. Garth, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge and belief:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of the date of the Report.

---

| | |
|:---|:---|
| */s/* | *Daniel T. Scavilla* |
| | Daniel T. Scavilla |
| | President and |
| | Chief Executive Officer |

---

November 6, 2025

<br>